<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fluoxetine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fluoxetine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fluoxetine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12486" href="/d/html/12486.html" rel="external">see "Fluoxetine: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13315" href="/d/html/13315.html" rel="external">see "Fluoxetine: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708805"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidality and antidepressant drugs:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk compared with placebo of suicidal thinking and behavior (suicidality) in short-term studies in children, adolescents, and young adults with major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of fluoxetine or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared with placebo in adults 65 years and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Appropriately monitor and closely observe patients of all ages who are started on antidepressant therapy for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication with the prescribing health care provider.</p>
<p style="text-indent:-2em;margin-left:2em;">Fluoxetine is approved for use in children with MDD (aged 8 years and older) and obsessive-compulsive disorder (OCD; aged 7 years and older). Sarafem is not approved for use in children.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F172714"><span class="drugH1">Brand Names: US</span>
<ul>
<li>PROzac;</li>
<li>Sarafem [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866936"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>ACH-FLUoxetine;</li>
<li>ACT FLUoxetine [DSC];</li>
<li>AG-Fluoxetine;</li>
<li>APO-FLUoxetine;</li>
<li>Auro-FLUoxetine;</li>
<li>BIO-FLUoxetine;</li>
<li>DOM-FLUoxetine;</li>
<li>JAMP-FLUoxetine;</li>
<li>M-FLUoxetine;</li>
<li>MINT-FLUoxetine;</li>
<li>NRA-Fluoxetine;</li>
<li>Odan-FLUoxetine;</li>
<li>PMS-FLUoxetine;</li>
<li>PRIVA-FLUoxetine [DSC];</li>
<li>PRO-FLUoxetine;</li>
<li>PROzac;</li>
<li>RIVA-FLUoxetine;</li>
<li>SANDOZ FLUoxetine [DSC];</li>
<li>TEVA-FLUoxetine</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F172763"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidepressant, Selective Serotonin Reuptake Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F172719"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Some experts suggest lower starting doses of 5 to 10 mg/day and gradual titration in increments of ≤10 mg, particularly in patients with anxiety who are sensitive to antidepressant-associated overstimulation effects (eg, anxiety, insomnia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018c','lexi-content-ref-Stein.2018','lexi-content-ref-35900161']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018c','lexi-content-ref-Stein.2018','lexi-content-ref-35900161'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d98a9598-5db0-4f0c-a3c4-96cdecc00d76">Binge eating disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Binge eating disorder (off-label use):</b>
<b>Oral:</b> Immediate release: Initial: 10 to 20 mg once daily; may increase dose based on response and tolerability in increments of 10 to 20 mg at intervals ≥1 week up to 80 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12444817','lexi-content-ref-18598735','lexi-content-ref-Sysko.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12444817','lexi-content-ref-18598735','lexi-content-ref-Sysko.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1969751f-c027-4072-874e-d4df29195cbe">Bipolar disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder:</b>
<i>Depressive episodes:</i>
<b>Oral:</b> Immediate release: Initial: 20 mg once daily in the evening in combination with olanzapine (preferred), another second-generation antipsychotic, or antimanic agent; may increase dose in 10 to 20 mg increments every 1 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bobo.1','lexi-content-ref-Kupka.2018','lexi-content-ref-14609883','lexi-content-ref-20148751','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bobo.1','lexi-content-ref-Kupka.2018','lexi-content-ref-14609883','lexi-content-ref-20148751','lexi-content-ref-manu.1'])">Ref</a></span>); usual dose range: 20 to 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kupka.2018','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kupka.2018','lexi-content-ref-manu.1'])">Ref</a></span>). May also use the fixed-dose combination instead of the separate components. See <i>
<b>Dosing conversion</b></i> below for conversion to or from olanzapine/fluoxetine fixed-dose combination.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88be5c8f-c670-41f5-94ab-670c50aba438">Body dysmorphic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Body dysmorphic disorder (BDD)</b>
<b>(off-label use):</b>
<b>Oral:</b> Immediate release: Initial: 20 mg once daily; may increase dose gradually based on response and tolerability in increments of 20 mg every 2 to 3 weeks to a usual dose of 70 to 80 mg/day by week 6 to 10 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11926939','lexi-content-ref-Phillips.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11926939','lexi-content-ref-Phillips.2018'])">Ref</a></span>). Doses up to 120 mg/day, if tolerated, may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Phillips.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Phillips.2018'])">Ref</a></span>). <b>Note:</b> An adequate trial for assessment of effect in BDD is 12 to 16 weeks, including maximum tolerated doses for at least 3 to 4 of those weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Phillips.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Phillips.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09d5012d-4c68-41f6-9a1f-54da08b78eeb">Bulimia nervosa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bulimia nervosa:</b>
<b>Oral:</b> Immediate release: Initial: 20 mg once daily; may increase dose gradually (eg, at intervals ≥1 week) based on response and tolerability in 20 mg increments up to a target dose of 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18598735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18598735'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Manufacturer's labeling: Dosing in prescribing information may not reflect current clinical practice. Initial: 60 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e693ed5-2ef9-4d22-beb4-041e9bcff02f">Fibromyalgia, refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fibromyalgia, refractory (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients not responsive to first-line agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27377815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27377815'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Immediate release: Initial: 20 mg once daily; may increase dose based on response and tolerability in 10 to 20 mg increments at ≥2-week intervals up to 80 mg/day. Mean dose in clinical trials was 45 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11893345','lexi-content-ref-27377815']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11893345','lexi-content-ref-27377815'])">Ref</a></span>). In patients with an insufficient response to first-line monotherapy, some experts suggest low-dose combination therapy (eg, fluoxetine 20 mg/day with a tricyclic antidepressant) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8912507','lexi-content-ref-Goldenberg.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8912507','lexi-content-ref-Goldenberg.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder (off-label use): Oral:</b> Immediate release: Initial: 10 to 20 mg once daily; may gradually increase dose based on response and tolerability in 10 to 20 mg increments at intervals of ≥1 week up to 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33321509','lexi-content-ref-Craske.1','lexi-content-ref-Hirsch.2018c']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33321509','lexi-content-ref-Craske.1','lexi-content-ref-Hirsch.2018c'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b>
<b>Oral:</b> Immediate release: Initial: 20 mg once daily; may increase dose based on response and tolerability in 20 mg increments at intervals ≥1 week up to a maximum dose of 80 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9988054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9988054'])">Ref</a></span>). Usual dose: 20 to 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010'])">Ref</a></span>). <b>Note:</b> For treatment-resistant depression, combination with olanzapine or another second-generation antipsychotic may be used; in major depression with psychotic features, fluoxetine plus an antipsychotic is standard treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-24801768','lexi-content-ref-15232326']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-24801768','lexi-content-ref-15232326'])">Ref</a></span>). May consider use of the fixed-dose combination instead of the separate components. See <i>
<b>Dosing conversions</b></i> below for conversion to or from the olanzapine/fluoxetine fixed-dose combination.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder:</b>
<b>Oral:</b> Immediate release: Initial: 10 to 20 mg once daily; may increase dose gradually in 20 mg increments at intervals ≥1 week based on response and tolerability; recommended range: 40 to 80 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17849776','lexi-content-ref-11199947','lexi-content-ref-Simpson.2018','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17849776','lexi-content-ref-11199947','lexi-content-ref-Simpson.2018','lexi-content-ref-manu.1'])">Ref</a></span>). Based on clinical experience, some patients may require up to 120 mg/day for a response; however, adverse effects may increase (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17849776','lexi-content-ref-Simpson.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17849776','lexi-content-ref-Simpson.2018'])">Ref</a></span>). <b>Note:</b> An adequate trial for assessment of effect in OCD is considered to be ≥6 weeks at maximum tolerated dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27249090']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27249090'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35322c81-c95a-4c47-baaf-72001a1c63ee">Panic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder:</b>
<b>Oral:</b> Immediate release: Initial: 5 to 10 mg once daily; after 3 to 7 days, gradually increase dose based on response and tolerability in 5 to 10 mg increments at intervals ≥1 week up to a usual dose of 20 to 40 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2009']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2009'])">Ref</a></span>). Maximum dose: 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33aa39f3-80b9-497a-8725-78dfd54c167a">Posttraumatic stress disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttraumatic stress disorder (PTSD) (off-label use):</b>
<b>Oral:</b> Immediate release: Initial: 10 to 20 mg once daily; may increase dose based on response and tolerability in 10 to 20 mg increments at intervals ≥1 week up to 80 mg/day. Usual dosage range in clinical trials: 20 to 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10621763','lexi-content-ref-11926718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10621763','lexi-content-ref-11926718'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03008e1c-e898-491f-b522-256bb5260378">Premature ejaculation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Premature ejaculation (off-label use):</b> Limited data available: <b>Oral:</b> Immediate release: Initial: 20 mg once daily; may increase dose based on response and tolerability after ≥1 week (some experts suggest 3- to 4-week titration intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Khera.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Khera.2018'])">Ref</a></span>)) to 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8863556','lexi-content-ref-31808410']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8863556','lexi-content-ref-31808410'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c36dd6b3-72d8-44c0-9113-9b954af8885b">Premenstrual dysphoric disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Premenstrual dysphoric disorder (PMDD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Continuous daily dosing regimen:</b></i>
<b>Oral:</b> Immediate release: Initial: 10 mg once daily; increase to usual effective dose of 20 mg once daily over the first month; in a subsequent menstrual cycle, a further increase to 30 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:2em;">
<i>
<b>Intermittent regimens:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Luteal phase dosing regimen:</i>
<b>Oral:</b> Immediate release: Initial: 10 mg once daily during the luteal phase of menstrual cycle only (ie, beginning therapy 14 days before anticipated onset of menstruation and continued to the onset of menses); over the first month, may increase to usual effective dose of 20 mg once daily during the luteal phase; in a subsequent menstrual cycle, a further increase to 30 mg/day during the luteal phase may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Symptom-onset dosing regimen (off-label dosing):</i>
<b>Oral:</b> Limited data available: Immediate release: 10 mg once daily from the day of symptom onset until a few days after the start of menses; over the first month, may increase dose based on response and tolerability up to 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aa5a69-6727-4715-b53a-79a3f9ae11c6">Social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder (off-label use):</b>
<b>Oral:</b> Immediate release: Initial: 10 to 20 mg once daily; after ~6 weeks may gradually increase dose based on response and tolerability in 10 mg increments at intervals of ≥1 week up to 60 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15466674','lexi-content-ref-Stein.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15466674','lexi-content-ref-Stein.2018'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Dosing conversion:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Delayed release (once-weekly formulation): </i>Immediate-release fluoxetine 20 mg/day = delayed-release fluoxetine 90 mg/week. When converting from immediate-release fluoxetine daily dosing, initiate delayed-release fluoxetine (90 mg once weekly) 7 days after the last 20 mg/day dose of immediate-release fluoxetine. Patients must be stabilized on immediate-release fluoxetine 20 mg once daily prior to switching.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Olanzapine/fluoxetine fixed-dose combination:</i> When using individual components of fluoxetine with olanzapine rather than fixed-dose combination product, corresponding approximate dosage equivalents are as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 2.5 mg + fluoxetine 20 mg = combination strength 3/25</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 5 mg + fluoxetine 20 mg = combination strength 6/25</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 12.5 mg + fluoxetine 20 mg = combination strength 12/25</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 5 mg + fluoxetine 50 mg = combination strength 6/50</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 12.5 mg + fluoxetine 50 mg = combination strength 12/50</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy:</b></i> When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 1 to 4 weeks) to minimize withdrawal symptoms and detect re-emerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include prior history of antidepressant withdrawal symptoms or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019'])">Ref</a></span>). If necessary, some clinicians allow for abrupt discontinuation based on fluoxetine's long half-life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Switching antidepressants:</b></i> Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from an MAOI. A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, and pharmacodynamics), and the degree of symptom control desired. If necessary, some clinicians allow for abrupt discontinuation based on fluoxetine's long half-life (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019','lexi-content-ref-Hirsch.2018b','lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019','lexi-content-ref-Hirsch.2018b','lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of fluoxetine.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 5 weeks to elapse between discontinuing fluoxetine and initiation of an MAOI.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990895"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6610522','lexi-content-ref-3871765','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6610522','lexi-content-ref-3871765','lexi-content-ref-manu.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (fluoxetine and its metabolite) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6610522']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6610522'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9565715','lexi-content-ref-8666216','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9565715','lexi-content-ref-8666216','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988013"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use lower doses (up to 50% reduction) and less frequent dosing intervals in patients with cirrhosis and chronic liver disease; use with caution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846','lexi-content-ref-25175904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846','lexi-content-ref-25175904'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F172720"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar):</b> Oral: Some patients may require an initial dose of 10 mg once daily with dosage increases of 10 to 20 mg every several weeks as tolerated; should not be taken at night unless patient experiences sedation. Refer to adult dosing; use with caution given the long half-life of fluoxetine.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosing conversion:</i></b> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Discontinuation of therapy:</b></i> Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Switching antidepressants:</b></i> Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F172738"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13315" href="/d/html/13315.html" rel="external">see "Fluoxetine: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> When using oral solutions, multiple concentrations may be available (commercially available [4 mg/mL] and compounded solutions [eg, 1 mg/mL, 2 mg/mL]); take precautions to verify appropriate product selection and avoid confusion between the different concentrations; dose should be clearly presented as mg.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e83bc66-3e6e-49b3-ab21-449ee2b4f882">Anxiety disorders</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anxiety disorders:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Fluoxetine therapy should be initiated at a low dose with a slow titration to reduce the potential for behavioral activation/agitation that may occur with therapy initiation particularly in younger children. Conservatively, fluoxetine dose titration at 3- to 4-week intervals has been suggested due to its long half-life; however, some patients with more severe symptoms may require more rapid titration; in trials, dose titration in weekly increments has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401','lexi-content-ref-12649628','lexi-content-ref-8935208','lexi-content-ref-9192539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401','lexi-content-ref-12649628','lexi-content-ref-8935208','lexi-content-ref-9192539'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Generalized anxiety, separation anxiety, panic disorders:</b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>In pediatric patients, selective serotonin reuptake inhibitor (SSRI) therapy is considered first-line pharmacologic treatment for moderate to severe anxiety disorders in combination with cognitive behavioral therapy (CBT); of the SSRIs with positive pediatric data evaluated in the AHRQ/Mayo review (fluoxetine, fluvoxamine, paroxetine, and sertraline), a preferred SSRI has not been defined; therapeutic selection should be based on pharmacokinetic and pharmacodynamic data, patient tolerability, cost, and unique risks/precautions with specific agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401','lexi-content-ref-Wang.1','lexi-content-ref-12649628','lexi-content-ref-29099547','lexi-content-ref-26660158','lexi-content-ref-9192539','lexi-content-ref-25449861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401','lexi-content-ref-Wang.1','lexi-content-ref-12649628','lexi-content-ref-29099547','lexi-content-ref-26660158','lexi-content-ref-9192539','lexi-content-ref-25449861'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to &lt;12 years: Oral: Immediate release: Initial: 5 mg once daily, may slowly titrate as needed; suggested target dose range: 10 to 20 mg once daily; maximum daily dose: 40 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12649628','lexi-content-ref-9192539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12649628','lexi-content-ref-9192539'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: Oral: Immediate release: Initial: 10 mg once daily, may slowly titrate as needed; suggested target dose range: 20 to 40 mg once daily; usual maximum daily dose: 60 mg/<b>day </b>although use of doses up to 80 mg/day has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12649628','lexi-content-ref-9192539','lexi-content-ref-McVoy.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12649628','lexi-content-ref-9192539','lexi-content-ref-McVoy.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Selective mutism: </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Limited data available: Children ≥5 years and Adolescents: Oral: Immediate release: Initial: 5 or 10 mg once daily for ≥7 days, then increase by doubling dose to 10 or 20 mg once daily for 7 days; may further titrate in 20 mg/day increments, if needed, every 2 weeks; maximum daily dose: 60 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29320378','lexi-content-ref-8935208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29320378','lexi-content-ref-8935208'])">Ref</a></span>). Dosing is based on an open-label study of 21 pediatric patients (age: 5 to 14 years); positive responses were reported in 76% of patients and required a dose of at least 20 mg/<b>day</b>; mean final dose: 28.1 mg/<b>day</b> (1.1 mg/kg/<b>day</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8935208']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8935208'])">Ref</a></span>) and a small (n= 5) single-case design, placebo-controlled trial (ages: 5 to 14 years) with a final dose of 20 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29320378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29320378'])">Ref</a></span>). To fully assess therapeutic response, a therapeutic trial of at least 9 to 12 weeks or longer has been suggested (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7961338','lexi-content-ref-8935208','lexi-content-ref-18225967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7961338','lexi-content-ref-8935208','lexi-content-ref-18225967'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2be5d1b7-1f22-43b5-ba05-d622b2fdec4a">Anorexia nervosa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anorexia nervosa:</b> Limited data available; efficacy results variable:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use in combination with psychosocial intervention or CBT; SSRI antidepressants have not been shown effective during the acute phases of illness; however, they may be considered for comorbid mental health conditions once weight has been restored (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33386343','lexi-content-ref-25901778','lexi-content-ref-32021688','lexi-content-ref-25351912']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33386343','lexi-content-ref-25901778','lexi-content-ref-32021688','lexi-content-ref-25351912'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: Immediate release: Initial: 20 mg once daily; may titrate in 20 mg increments (similar to other indications in adolescents) at monthly intervals; typical reported dosing range: 20 to 40 mg/day; reported maximum daily dose: 60 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15725429','lexi-content-ref-11297722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15725429','lexi-content-ref-11297722'])">Ref</a></span>). Dosing based on a small, prospective, double-blind, placebo-controlled trial of 35 patients (fluoxetine: n=16; mean age: 23 ± 9 years) which showed reduced relapse (increased weight, decrease in symptoms) with 1 year of fluoxetine and mean dose of 38 ± 21 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11297722']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11297722'])">Ref</a></span>). Other randomized controlled trials with similar dosing have not shown fluoxetine therapy effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15725429','lexi-content-ref-16772623']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15725429','lexi-content-ref-16772623'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09d5012d-4c68-41f6-9a1f-54da08b78eeb">Bulimia nervosa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bulimia nervosa:</b> Limited data available: <b>Note:</b> Antidepressant therapy is recommended to target symptoms of obsessionality, anxiety, and depression in combination with CBT (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33386343','lexi-content-ref-25901778']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33386343','lexi-content-ref-25901778'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: Immediate release: Initial: 20 mg once daily for 3 days, then 40 mg once daily for 3 days, then 60 mg once daily; dosing based on an open-label study of 10 pediatric patients (age: 12 to 18 years) which showed significant decrease in number of weekly purges; other reports describe use in adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Gable.2005','lexi-content-ref-14642021','lexi-content-ref-21115584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Gable.2005','lexi-content-ref-14642021','lexi-content-ref-21115584'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae35da88-7e3c-40ea-9daa-1be1ccfd22b6">Depression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Depression: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>In the management of depression in children and adolescents, if pharmacotherapy is deemed necessary with/without psychotherapeutic interventions, an SSRI should be used first-line; fluoxetine has the strongest efficacy evidence and is preferred as first-line SSRI option in absence of drug-drug interactions, risk factors for bipolar comorbidity, or family (eg, parent, sibling) history of poor response to fluoxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-APA.1','lexi-content-ref-30063169','lexi-content-ref-31577402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-APA.1','lexi-content-ref-30063169','lexi-content-ref-31577402'])">Ref</a></span>). Therapy should be initiated at a low dose and titrated every 1 to 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30397569']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30397569'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 8 to &lt;12 years: Oral: Immediate release: Initial: 5 or 10 mg once daily; usual daily dose: 10 mg once daily; if needed, may increase dose to 20 mg once daily after 1 to 2 weeks; some pediatric patients may require higher doses up to 40 mg/day; maximum daily dose: 40 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16434782','lexi-content-ref-18030077','lexi-content-ref-30397569','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16434782','lexi-content-ref-18030077','lexi-content-ref-30397569','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Oral: Immediate release: Initial: 10 to 20 mg once daily; may increase in 10 to 20 mg increments every 1 to 2 weeks; usual effective dose: 20 to 40 mg once daily; maximum daily dose: 60 mg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-18030077','lexi-content-ref-30063169','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-18030077','lexi-content-ref-30063169','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1435ae96-b52f-4d3c-8ed6-20477be8c39b">Depression associated with bipolar I disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Depression associated with bipolar I disorder (in combination with olanzapine):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents: Oral: Immediate release: Initial: 20 mg in the evening; adjust dose, if needed, as tolerated; safety of fluoxetine doses &gt;50 mg in combination with doses &gt;12 mg of olanzapine has not been studied in pediatrics.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> When using individual components of fluoxetine with olanzapine rather than fixed-dose combination product (Symbyax), approximate dosage correspondence is as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 2.5 mg + fluoxetine 20 mg = Symbyax 3/25.</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 5 mg + fluoxetine 20 mg = Symbyax 6/25.</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 12.5 mg + fluoxetine 20 mg = Symbyax 12/25.</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 5 mg + fluoxetine 50 mg = Symbyax 6/50.</p>
<p style="text-indent:-2em;margin-left:6em;">Olanzapine 12.5 mg + fluoxetine 50 mg = Symbyax 12/50.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder (OCD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In the management of OCD in children and adolescents, if pharmacotherapy deemed necessary it should be in combination with CBT and an SSRI should be used first-line; a preferred agent has not been identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22176943','lexi-content-ref-15507582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22176943','lexi-content-ref-15507582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children preschool to &lt;7 years: Limited data available:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Use should be reserved for patients with moderate to severe symptoms which cause significant distress or significant impairment in the child's relationships, daily routine at home, or child care setting, and continue despite psychotherapeutic interventions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18030077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18030077'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: Immediate release: 2.5 to 5 mg once daily initially; continue for 10 to 12 weeks to assess initial response; monitor closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22176943','lexi-content-ref-18030077']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22176943','lexi-content-ref-18030077'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥7 years and Adolescents: Oral: Immediate release (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22176943','lexi-content-ref-31447707','lexi-content-ref-12447029','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22176943','lexi-content-ref-31447707','lexi-content-ref-12447029','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Lower weight Children: Initial: 5 to 10 mg once daily; if needed, may increase dose after several weeks; usual daily dose: 20 to 30 mg/<b>day</b>; minimal experience with doses &gt;20 mg/<b>day</b>; no experience with doses &gt;60 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Higher weight Children and Adolescents: Initial: 10 mg once daily; increase dose to 20 mg once daily after 2 weeks; may increase dose after several more weeks; usual daily dose: 20 to 60 mg/<b>day</b>; however, doses of 80 mg/day may be considered in some cases.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Consider planning antidepressant discontinuation for lower-stress times, recognizing non-illness-related factors could cause stress or anxiety and be misattributed to antidepressant discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29337001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29337001'])">Ref</a></span>). Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. After long-term (years) antidepressant treatment, WFSBP guidelines recommend tapering over 4 to 6 months, with close monitoring during and for 6 months after discontinuation. If intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching antidepressants:</b> Evidence for ideal antidepressant switching strategies in pediatric patients is sparse; strategies described in pediatric guidelines include a conservative approach (tapering and discontinuing the first SSRI before adding the second) and cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant). While consensus does not exist regarding which approach to utilize, it is important to note that the conservative approach runs the risk for exacerbation of symptoms or discontinuation syndrome; cross-titration may avoid these risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401'])">Ref</a></span>). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from a monamine oxidase inhibitors. While not as common of a strategy, a direct switch may be considered when switching to another agent in the same or similar class (eg, when switching between 2 SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51112080"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥7 years and Adolescents: Adjustment not routinely needed. With chronic administration, additional accumulation of fluoxetine or norfluoxetine may occur in patients with severely impaired renal function. Based on experience in adult patients, not removed by hemodialysis; use of lower dose or less frequent dosing is not usually necessary.</p></div>
<div class="block dohp drugH1Div" id="F51112081"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥7 years and Adolescents: Elimination half-life of fluoxetine is prolonged in patients with hepatic impairment; lower doses or less frequent administration are recommended.</p></div>
<div class="block arsc drugH1Div" id="F54703991"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activation of mania or hypomania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (when used as monotherapy) may precipitate a mixed/manic episode in patients with bipolar disorder. Treatment-emergent <b>mania</b> or <b>hypomania</b> in patients with unipolar major depressive disorder (MDD) have been reported, as many cases of bipolar disorder present in episodes of MDD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-9387089','lexi-content-ref-9639082','lexi-content-ref-1938809','lexi-content-ref-19630612','lexi-content-ref-6362443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-9387089','lexi-content-ref-9639082','lexi-content-ref-1938809','lexi-content-ref-19630612','lexi-content-ref-6362443'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-28558366','lexi-content-ref-26667012','lexi-content-ref-19958306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-28558366','lexi-content-ref-26667012','lexi-content-ref-19958306'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; a systematic review observed that the risk of switching increased significantly within the initial 2 years of antidepressant treatment in patients with unipolar MDD receiving an antidepressant as monotherapy, but not thereafter (up to 4.6 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depressive episode with psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age at onset of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antidepressant resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32215771','lexi-content-ref-29873955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32215771','lexi-content-ref-29873955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs), including fluoxetine, may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/or anticoagulants in adult and pediatric patients. Multiple observational studies have found an association with SSRI use and a variety of bleeding complications, ranging from <b>bruise</b>, hematoma, <b>petechia</b>, purpuric disease, and <b>epistaxis</b> to <b>cerebrovascular accident</b>, <b>upper gastrointestinal hemorrhage</b>, intracranial hemorrhage, postpartum hemorrhage, and intraoperative bleeding, although conflicting evidence also exists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23699725','lexi-content-ref-30081645','lexi-content-ref-28636812','lexi-content-ref-21749836','lexi-content-ref-29536379','lexi-content-ref-25983210','lexi-content-ref-28577352','lexi-content-ref-24314591','lexi-content-ref-27323598','lexi-content-ref-31206390','lexi-content-ref-10755580','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-8826562','lexi-content-ref-27834194','lexi-content-ref-28766108','lexi-content-ref-25749013','lexi-content-ref-28141599']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23699725','lexi-content-ref-30081645','lexi-content-ref-28636812','lexi-content-ref-21749836','lexi-content-ref-29536379','lexi-content-ref-25983210','lexi-content-ref-28577352','lexi-content-ref-24314591','lexi-content-ref-27323598','lexi-content-ref-31206390','lexi-content-ref-10755580','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-8826562','lexi-content-ref-27834194','lexi-content-ref-28766108','lexi-content-ref-25749013','lexi-content-ref-28141599'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Possibly via decreased platelet serotonin concentrations and inhibition of serotonin-mediated platelet activation leading to subsequent platelet dysfunction. Fluoxetine is considered to display high affinity for the serotonin receptor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24314591','lexi-content-ref-18188866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24314591','lexi-content-ref-18188866'])">Ref</a></span>). SSRIs may also increase gastric acidity, which can increase the risk of GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; bleeding risk is likely delayed for several weeks until SSRI-induced platelet serotonin depletion becomes clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190637'])">Ref</a></span>); although the onset of bleeding may be more unpredictable if patients are taking concomitant antiplatelets, anticoagulants, or nonsteroidal anti-inflammatory drugs (NSAIDs). For upper GI bleeding, some studies have found risk to be the highest in the first 28 to 30 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19716436','lexi-content-ref-19491861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19716436','lexi-content-ref-19491861'])">Ref</a></span>), whereas another study reported a median time of onset of 25 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17919277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17919277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of anticoagulants and/or antiplatelets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21948719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21948719'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-17506225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-17506225'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of NSAIDs increase the risk for upper GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fragility fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Limited data from observational studies involving mostly older adults (≥50 years of age) suggest selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of bone fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20703452','lexi-content-ref-30247774','lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406','lexi-content-ref-31140587','lexi-content-ref-18219438','lexi-content-ref-26126579']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20703452','lexi-content-ref-30247774','lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406','lexi-content-ref-31140587','lexi-content-ref-18219438','lexi-content-ref-26126579'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; mechanism not fully elucidated; postulated to be through a direct effect by SSRIs on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22659406','lexi-content-ref-30775508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22659406','lexi-content-ref-30775508'])">Ref</a></span>). SSRIs may also contribute to fall risk, contributing to the incidence of fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27495351']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27495351'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; risk appears to increase after initiation and may continue to increase with long-term use. A meta-analysis found risk of fracture increased from 2.9% over 1 year to 5.4% over 2 years; within 5 years, risk increased to 13.4% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Long-term use may be a risk factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20703452','lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20703452','lexi-content-ref-30247774'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">A wide variety of <b>hypersensitivity reactions </b>have been reported rarely with fluoxetine, including severe systemic reactions; reactions include <b>dermatitis</b>, urticaria, angioedema, eosinophilia, <b>Stevens-Johnson syndrome </b>(SJS), <b>toxic epidermal necrolysis </b>(TEN), <b>drug reaction with eosinophilia and systemic symptoms</b> (DRESS), <b>serum-like sickness reaction</b>, <b>vasculitis</b> (eg, leukocytoclastic vasculitis, <b>Henoch-Schönlein purpura</b>), and certain pulmonary inflammatory diseases (eg, <b>hypersensitivity pneumonitis, pulmonary granuloma</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30296343','lexi-content-ref-8002659','lexi-content-ref-10405699','lexi-content-ref-8730028','lexi-content-ref-7781383','lexi-content-ref-18204349','lexi-content-ref-2589557','lexi-content-ref-27467827','lexi-content-ref-29073757','lexi-content-ref-28523892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30296343','lexi-content-ref-8002659','lexi-content-ref-10405699','lexi-content-ref-8730028','lexi-content-ref-7781383','lexi-content-ref-18204349','lexi-content-ref-2589557','lexi-content-ref-27467827','lexi-content-ref-29073757','lexi-content-ref-28523892'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Non-dose-related; immunologic. Severe cutaneous adverse reactions, namely SJS/TEN, DRESS, acute generalized exanthematous pustulosis), are delayed type IV hypersensitivity reactions involving a T-cell mediated drug-specific immune response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Intermediate; in the majority of cases, onset of symptoms generally occurred from 1 to 4 weeks after initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30296343','lexi-content-ref-7781383','lexi-content-ref-2589557','lexi-content-ref-27467827','lexi-content-ref-28523892']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30296343','lexi-content-ref-7781383','lexi-content-ref-2589557','lexi-content-ref-27467827','lexi-content-ref-28523892'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are associated with syndrome of inappropriate antidiuretic hormone secretion (<b>SIADH</b>) and/or <b>hyponatremia, </b>including severe cases, predominantly in the elderly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8329791','lexi-content-ref-8811276','lexi-content-ref-25262043','lexi-content-ref-14728721','lexi-content-ref-27773479','lexi-content-ref-16896026','lexi-content-ref-27323598','lexi-content-ref-18317501']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8329791','lexi-content-ref-8811276','lexi-content-ref-25262043','lexi-content-ref-14728721','lexi-content-ref-27773479','lexi-content-ref-16896026','lexi-content-ref-27323598','lexi-content-ref-18317501'])">Ref</a></span>). Hyponatremia is reversible with discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8804257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8804257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May cause SIADH via release of antidiuretic hormone (ADH) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; usually develops within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower baseline serum sodium concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of hyponatremia (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Symptoms of psychosis (potential risk factors) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are associated with <b>acute angle-closure glaucoma</b> (AACG) in case reports and a case-controlled study. AACG may cause symptoms including eye pain, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1926918','lexi-content-ref-8795389','lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1926918','lexi-content-ref-8795389','lexi-content-ref-27993931'])">Ref</a></span>). In addition, SSRIs may be associated with an increased risk of cataract development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28342338','lexi-content-ref-24631758']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28342338','lexi-content-ref-24631758'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> AACG: Unclear; hypothesized SSRIs may increase the intraocular pressure via serotonergic effects on ciliary body muscle activation and pupil dilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27135704','lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27135704','lexi-content-ref-27993931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For AACG:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>≥50 years of age (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Hyperopia (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Personal or family history of AACG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>• </i>Inuit or Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported and typically occurs with coadministration of multiple serotonergic drugs but can occur following a single serotonergic agent at therapeutic doses, particularly with fluoxetine use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26082973','lexi-content-ref-26240751','lexi-content-ref-10645303','lexi-content-ref-27999518','lexi-content-ref-25540831']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26082973','lexi-content-ref-26240751','lexi-content-ref-10645303','lexi-content-ref-27999518','lexi-content-ref-25540831'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614','lexi-content-ref-15784664','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake and/or impair serotonin metabolism (eg, monamine oxidase inhibitors [MAOIs]). Of note, concomitant use of some serotonergic agents, such as MAOIs, are contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are commonly associated with <b>sexual disorders</b> in both men and women. The following adverse reactions have been associated with SSRI use: Ejaculatory delay, orgasm disturbance, <b>anorgasmia,</b> erectile dysfunction, <b>decreased libido, </b>and loss of libido (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955469','lexi-content-ref-2786344','lexi-content-ref-11229449','lexi-content-ref-9292833','lexi-content-ref-19440080','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955469','lexi-content-ref-2786344','lexi-content-ref-11229449','lexi-content-ref-9292833','lexi-content-ref-19440080','lexi-content-ref-26003261'])">Ref</a></span>). <b>Priapism</b> and decreased genital anesthesia have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18173768','lexi-content-ref-8683851','lexi-content-ref-10755087','lexi-content-ref-8417566','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18173768','lexi-content-ref-8683851','lexi-content-ref-10755087','lexi-content-ref-8417566','lexi-content-ref-26003261'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Increases in serotonin may affect other hormones and neurotransmitters involved in sexual function; in particular, testosterone's effect on sexual arousal and dopamine's role in achieving orgasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955469','lexi-content-ref-10333979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955469','lexi-content-ref-10333979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; one longitudinal study observed an onset of sexual dysfunction within the first 6 weeks of treatment with fluoxetine (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29588433']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29588433'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (sexual dysfunction is commonly associated with depression; SSRI-associated sexual dysfunction may be difficult to differentiate in treated patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12243609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12243609'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of <b>suicidal ideation</b> and <b>suicidal tendencies</b> in pediatric and young adult patients (18 to 24 years of age) in short-term studies. In adults &gt;24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults ≥65 years of age a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1501465','lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-7875951','lexi-content-ref-18056231','lexi-content-ref-2301661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1501465','lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-7875951','lexi-content-ref-18056231','lexi-content-ref-2301661'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to longer-term use (ie, &gt;4 months).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (risk of suicide associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Withdrawal syndrome, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, shock-like sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability, mania), have been reported, primarily following abrupt discontinuation. Withdrawal symptoms may also occur following gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705','lexi-content-ref-15906018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705','lexi-content-ref-15906018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the selective serotonin reuptake inhibitor. Other neurotransmission systems, including increased glutamine and dopamine, may also be affected as well as the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420','lexi-content-ref-23596418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420','lexi-content-ref-23596418'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; expected onset is 1 to 10 days (following either abrupt or tapered discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705','lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705','lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant treatment that has lasted &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972','lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972','lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F172677"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in adults, unless otherwise noted.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (1% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Libido table link" class="lexi-table-link" data-table-id="lexi-content-decreased-libido" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-libido')">table 1</a>)</span><span class="table-link" style="display:none;">Decreased Libido</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Libido" frame="border" id="lexi-content-decreased-libido" rules="all">
<caption style="text-align:center;">
<b>Fluoxetine: Adverse Reaction: Decreased Libido</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fluoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fluoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">5%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bulimia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">450</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">267</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">MDD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1728</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">975</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">OCD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">89</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">425</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">342</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia (4% to 17%), diarrhea (8% to 18%), nausea (12% to 29%), xerostomia (9% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Sexual disorder (literature suggests an incidence ranging from 54% to 58%; can persist after discontinuation) (Csoka 2006; Higgins 2010; Montejo 2001; Montejo-Gonzalez 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (6% to 15%), asthenia (9% to 21%), drowsiness (5% to 17%; literature suggests it is more common in adults compared to children and adolescents) (Safer 2006), headache (21%), insomnia (10% to 33%), nervousness (8% to 14%), tremor (3% to 13%), yawning (≤11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis (10% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pain (≥1%), hypertension (≥1%), palpitations (≥1%), prolonged QT interval on ECG (≥1%; QTcF ≥450 msec<sup>3</sup>), vasodilation (1% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (7% to 8%), pruritus (3%), skin rash (2% to 6%)<span class="lexi-table-link-container"> (<a aria-label="Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-skin-rash')">table 2</a>)</span><span class="table-link" style="display:none;">Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Skin Rash" frame="border" id="lexi-content-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Fluoxetine: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fluoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fluoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bulimia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">450</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">267</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">MDD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1728</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">975</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">OCD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">266</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">89</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">425</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">342</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Heavy menstrual bleeding (children and adolescents: ≥2%), increased thirst (children and adolescents: ≥2%), weight loss (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (5%), dysgeusia (≥1%), dyspepsia (6% to 10%), flatulence (3%), increased appetite (≥1%), vomiting (3%; literature suggests prevalence is higher in adolescents compared to adults and is two- to threefold more prevalent in children compared to adults) (Safer 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ejaculatory disorder (2% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Ejaculatory Disorder table link" class="lexi-table-link" data-table-id="lexi-content-ejaculatory-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ejaculatory-disorder')">table 3</a>)</span><span class="table-link" style="display:none;">Ejaculatory Disorder</span>, erectile dysfunction (≤7%), urinary frequency (children and adolescents: ≥2%), urination disorder (≥1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ejaculatory Disorder" frame="border" id="lexi-content-ejaculatory-disorder" rules="all">
<caption style="text-align:center;">
<b>Fluoxetine: Adverse Reaction: Ejaculatory Disorder</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Fluoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Fluoxetine)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Bulimia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">OCD</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">116</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">43</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Panic disorder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">162</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">121</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (5%), agitation (children and adolescents: ≥2%), amnesia (≥1%), changes in thinking (2%), chills (≥1%), dizziness (9%), emotional lability (≥1%), personality disorder (children and adolescents: ≥2%), sleep disturbance (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity (children and adolescents: ≥2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Visual disturbance (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otalgia (≥1%), tinnitus (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (children and adolescents: ≥2%), flu-like symptoms (8% to 10%), sinusitis (5% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, angina pectoris, cardiac arrhythmia, edema, heart failure, hypotension, orthostatic hypotension, syncope, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, alopecia, ecchymoses, purpuric rash, skin photosensitivity</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria, amenorrhea, hypercholesterolemia, hypothyroidism, increased libido</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Aphthous stomatitis, bloody diarrhea, bruxism, cholelithiasis, colitis, duodenal ulcer, esophageal ulcer, gastritis, gastroenteritis, gastrointestinal ulcer, glossitis, hematemesis, melena, peptic ulcer</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Gynecological bleeding</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia, petechia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia, ataxia, balance impairment, delusion, depersonalization, euphoria, extrapyramidal reaction, hostility, hypertonia, migraine, myoclonus, paranoid ideation, suicidal tendencies</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, bursitis, gout, lower limb cramp, ostealgia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Mydriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Asthma, laryngeal edema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, pulmonary embolism, ventricular tachycardia (including torsades de pointes) (Wenzel-Seifert 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Dermatitis (Agrawal 2019), erythema multiforme, erythema nodosum, exfoliative dermatitis, psoriasis (new onset) (Tan Pei Lin 2010), Stevens-Johnson syndrome (Agrawal 2019), toxic epidermal necrolysis (Jonsson 2008)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Galactorrhea not associated with childbirth, gynecomastia, hyperprolactinemia, hypoglycemia, hypokalemia, hyponatremia (literature suggests incidence among selective serotonin reuptake inhibitors [SSRIs] ranges from &lt;1% to as high as 32%) (Jacob 2006; Kaya 2016), SIADH (Blacksten 1993)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Esophagitis, pancreatitis, upper gastrointestinal hemorrhage (Wee 2017)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Anorgasmia (Kline 1989), priapism (Javed 1996), sexual difficulty (decreased genital sensation) (Michael 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, bruise (Pai 1996), hemolytic anemia (immune-related), Henoch-Schonlein purpura (Süleyman 2016), immune thrombocytopenia, pancytopenia, thrombocytopenia (Yucel 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic jaundice, hepatic failure, hepatic necrosis, hepatotoxicity (Agrawal 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms (Vignesh 2017), hypersensitivity reaction (Beer 1994), nonimmune anaphylaxis, serum sickness-like reaction (Miller 1989)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anosmia (including hyposmia), cerebrovascular accident, hallucination, hyperactive behavior (including agitation, hyperactivation, hyperkinesis, restlessness; occurring in children at a two- to threefold higher incidence compared to adolescents) (Safer 2006), hypomania (Jerome 1991), mania (Settle 1984), memory impairment (Chavant 2011), neuroleptic malignant syndrome, obsessive compulsive disorder (worsening symptoms of trichotillomania) (Yektaş 2017), seizure (Hargrave 1992; Levine 1994), serotonin syndrome (Patel 2016), suicidal ideation (Teicher 1990), violent behavior</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Dyskinesia (Mander 1994), dystonia (Bilen 2008), laryngospasm, linear skeletal growth rate below expectation (children) (Weintrob 2006), lupus-like syndrome, tardive dyskinesia (Dubovsky 1996)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma (Ahmad 1991), cataract, optic neuritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis, hypersensitivity pneumonitis (Gonzalez-Rothi 1995), hyperventilation, pulmonary fibrosis, pulmonary granuloma (de Kerviler 1996), pulmonary hypertension</p></div>
<div class="block coi drugH1Div" id="F172694"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to fluoxetine or any component of the formulation; use of MAO inhibitors (concurrently, within 5 weeks of discontinuing fluoxetine, or within 2 weeks of discontinuing the MAO inhibitor); initiation of fluoxetine in a patient receiving linezolid or intravenous methylene blue; use with pimozide or thioridazine (<b>Note:</b> Thioridazine should not be initiated until 5 weeks after the discontinuation of fluoxetine.)</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Initiation of fluoxetine within 2 weeks of thioridazine discontinuation</p></div>
<div class="block war drugH1Div" id="F172674"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: QT prolongation and ventricular arrhythmia, including torsades de pointes, have occurred. Use with caution in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of prolonged QT, family history of prolonged QT or sudden cardiac death), other conditions that predispose to arrhythmias (eg, hypokalemia, hypomagnesemia, recent myocardial infarction [MI], uncompensated heart failure, bradyarrhythmias or other arrhythmias, concomitant use of other agents that prolong QT interval), or increased fluoxetine exposure (eg, overdose, hepatic impairment, use of CYP2D6 inhibitors, poor CYP2D6 metabolizer status, concomitant use of other highly protein-bound drugs). Consider ECG monitoring when initiating therapy in patients with risk factors for QT prolongation and ventricular arrhythmia. Consider discontinuing fluoxetine if ventricular arrhythmia suspected and initiate cardiac evaluation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with a history of MI or unstable heart disease; experience in these patients is limited.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and half-life and plasma concentrations are increased; a lower dosage may be needed in patients with cirrhosis. However, selective serotonin reuptake inhibitors such as fluoxetine are considered the safest antidepressants to use in chronic liver disease because of their relative lack of side effects and high therapeutic index (Mullish 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with a previous seizure disorder or conditions predisposing to seizures such as brain damage or alcoholism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: May also cause agitation, sleep disturbances, and excessive CNS stimulation in older adults. Given the long half-life and nonlinear disposition of the drug, use caution, particularly if they have systemic illness or are receiving multiple drugs for concomitant diseases.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Long half-life: Due to the long half-life of fluoxetine and its metabolites, the effects and interactions noted may persist for prolonged periods following discontinuation.</p></div>
<div class="block foc drugH1Div" id="F172686"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PROzac: 10 mg, 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 90 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/5 mL (5 mL [DSC], 120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sarafem: 10 mg [DSC], 20 mg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 60 mg</p></div>
<div class="block geq drugH1Div" id="F172670"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F172697"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (FLUoxetine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $39.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (FLUoxetine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $0.07 - $2.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.07 - $2.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.91 - $5.34</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (PROzac Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $17.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $17.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $30.41</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (FLUoxetine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/5 mL (per mL): $0.98 - $2.50</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (FLUoxetine HCl (PMDD) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $16.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $16.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (FLUoxetine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $2.87 - $4.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $4.20 - $4.94</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $10.44 - $12.19</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866937"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PROzac: 10 mg, 20 mg [contains butylparaben, edetate (edta) calcium disodium, fd&amp;c blue #1 (brilliant blue), methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/5 mL (120 ea, 120 mL)</p></div>
<div class="block adm drugH1Div" id="F7744183"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b></b>Bariatric surgery: Capsule, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Delayed-release capsule cannot be opened. Switch to IR tablet or oral solution dosed daily.</p></div>
<div class="block admp drugH1Div" id="F52612865"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food. For most pediatric uses (ie, anxiety, obsessive-compulsive disorder, depression, anorexia, bulimia), doses should be administered in the morning. When used concomitantly with olanzapine for bipolar I disorder and treatment-resistant depression, doses should be administered in the evening.</p></div>
<div class="block meg drugH1Div" id="F7873368"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Fluoxetine tablets: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F202133s009s016lbl.pdf%23page%3D36&amp;token=rpBpdT9ogDd8lCKE%2BgmkJwMUdJSkZt%2FeNzsIfnvaum848NkTiwYeub99jMXrm88nzGFX3VUOtDoimO%2BjbBaQmoxl0hkl%2FDxKToOusVvRXzyqWfEDce1ZhVGvcPoPNUaz&amp;TOPIC_ID=8465" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202133s009s016lbl.pdf#page=36</a></p>
<p style="text-indent:-2em;margin-left:4em;">Prozac: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F018936%2520s112lbl.pdf%23page%3D26&amp;token=Fpfe3GEOz6HzXXizfKQ%2Bq9M12jfX1P6Uh%2F%2B1Ximb8Hrf34gIedJOSnNxshuB4J2Z2fG9LS8fun4%2FZ%2BRq%2B1OsZJCrW2OTn2qapOgNjl8JEuPL75m2h1mrNWIOljVv5Y4r&amp;TOPIC_ID=8465" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/018936%20s112lbl.pdf#page=26</a></p>
<p style="text-indent:-2em;margin-left:4em;">Sarafem: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F021860s015lbl.pdf%23page%3D32&amp;token=gbeo0SiQdEMzrV46063bm%2F2H1KwJTmV%2Bxm7%2FUZ0BY%2F38zLG7LTNmLnjuLJsEinRPSXGyUZJTr2VCzUuZ4JvHMIpSWYFmzzS4GKq36ZuZYnV97xGTutUwpaq9CLzGTlmv&amp;TOPIC_ID=8465" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021860s015lbl.pdf#page=32</a></p></div>
<div class="block use drugH1Div" id="F172690"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bipolar disorder (excluding Sarafem):</b> As an adjunct to olanzapine (preferred), other antipsychotics, or antimanic agents for the treatment of depressive episodes associated with bipolar disorder (WFSBP [Grunze 2010]; manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Bulimia nervosa (excluding Sarafem):</b> Acute and maintenance treatment of binge eating and vomiting behaviors in patients with moderate to severe bulimia nervosa.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (unipolar) (excluding Sarafem):</b> Acute and maintenance treatment of unipolar major depressive disorder (MDD). Also, approved for acute treatment of treatment-resistant unipolar depression (patients with unipolar MDD who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) in combination with olanzapine or other antipsychotics (APA 2010).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder </b>
<b>(excluding Sarafem):</b> Acute and maintenance treatment of obsessions and compulsions in patients with obsessive-compulsive disorder.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder (excluding Sarafem):</b> Acute treatment of panic disorder with or without agoraphobia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Premenstrual dysphoric disorder (Sarafem only):</b> Treatment of premenstrual dysphoric disorder.</p></div>
<div class="block off-label drugH1Div" id="F25725575"><span class="drugH1">Use: Off-Label: Adult</span><p>Binge eating disorder; Body dysmorphic disorder; Fibromyalgia, refractory; Generalized anxiety disorder; Posttraumatic stress disorder; Premature ejaculation; Selective mutism; Social anxiety disorder</p></div>
<div class="block mst drugH1Div" id="F172774"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">FLUoxetine may be confused with DULoxetine, famotidine, Feldene, fluconazole, fluvastatin, fluvoxaMINE, fosinopril, furosemide, Loxitane [DSC], PARoxetine, thiothixene, vortioxetine</p>
<p style="text-indent:-2em;margin-left:4em;">PROzac may be confused with Paxil, Prelone, PriLOSEC, Prograf, Proscar, ProSom, Provera</p>
<p style="text-indent:0em;margin-left:2em;">Sarafem may be confused with Serophene</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Selective Serotonin Reuptake Inhibitors (SSRIs) are identified in the Beers Criteria as a potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Reneuron [Spain] may be confused with Remeron brand name for mirtazapine [US, Canada, and multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F172756"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (moderate), CYP2D6 (strong)</p></div>
<div class="block dri drugH1Div" id="F172679"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Amphetamines. Management: Monitor for amphetamine toxicities, including serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust dose as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: Aripiprazole dose reductions or avoidance are required for indications other than major depressive disorder. Dose adjustments vary based on formulation, initial starting dose, and the additional use of CYP3A4 inhibitors. See interact monograph for details<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Decrease aripiprazole lauroxil dose to next lower strength if used with strong CYP2D6 inhibitors for over 14 days. No dose adjustment needed if using the lowest dose (441 mg) or if a CYP2D6 PM. Max dose is 441 mg if also taking strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Atomoxetine.  Management: Initiate atomoxetine at a reduced dose (patients who weigh up to 70 kg: 0.5 mg/kg/day; adults or patients who weigh 70 kg or more: 40 mg/day) in patients receiving a strong CYP2D6 inhibitor. Increase to usual target dose after 4 weeks if needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belzutifan: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Belzutifan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: Selective Serotonin Reuptake Inhibitors may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Brexpiprazole.  Management: Reduce brexpiprazole dose to 50% of usual with strong CYP2D6 inhibitors, reduce to 25% of usual if used with both a strong CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor; these recommendations do not apply if treating major depressive disorder<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brivaracetam: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Brivaracetam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Broom: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Broom. Specifically, the concentrations of sparteine, a constituent of broom, may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: FLUoxetine may enhance the neuroexcitatory and/or seizure-potentiating effect of BuPROPion. BuPROPion may increase the serum concentration of FLUoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: FLUoxetine may increase the serum concentration of CarBAMazepine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carisoprodol: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Carisoprodol. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Carisoprodol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Charcoal, Activated: May decrease serum concentrations of the active metabolite(s) of FLUoxetine. Charcoal, Activated may decrease the serum concentration of FLUoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorpheniramine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Chlorpheniramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP2C19 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cilostazol. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving moderate inhibitors of CYP2C19. Monitor clinical response to cilostazol closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of FLUoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: May enhance the antiplatelet effect of FLUoxetine. Citalopram may enhance the serotonergic effect of FLUoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of Citalopram. Management: Limit citalopram dose to a maximum of 20 mg/day. Monitor for signs and symptoms of bleeding, QTc interval prolongation, or serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor) if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: FLUoxetine may enhance the QTc-prolonging effect of Clarithromycin. Clarithromycin may increase the serum concentration of FLUoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2D6 Inhibitors (Strong): May increase the serum concentration of FLUoxetine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Deutetrabenazine.  Management: The total daily dose of deutetrabenazine should not exceed 36 mg with concurrent use of a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexlansoprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Dexlansoprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Dextromethorphan. Management: Consider alternatives to this drug combination. The dose of dextromethorphan/bupropion product should not exceed 1 tablet once daily. Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: FLUoxetine may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Strong) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). DULoxetine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of DULoxetine. Management: Monitor for increased duloxetine effects/toxicities and signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperthermia, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Eliglustat.  Management: Eliglustat dose is 84 mg daily with CYP2D6 inhibitors. Use is contraindicated (COI) when also combined with strong CYP3A4 inhibitors. When also combined with a moderate CYP3A4 inhibitor, use is COI in CYP2D6 EMs or IMs and should be avoided in CYP2D6 PMs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Fenfluramine.  Management: Limit fenfluramine dose to 20 mg/day without concurrent stiripentol or to 17 mg/day with concomitant stiripentol and clobazam when used with a strong CYP2D6 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FluPHENAZine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of FluPHENAZine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Galantamine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Galantamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Avoid use of this combination if possible. If the combination cannot be avoided, monitor closely for evidence of reduced response to the selective serotonin reuptake inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iboga: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iboga. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor and monitor for increased iloperidone toxicities, including QTc interval prolongation and arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lansoprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Lansoprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofexidine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Lofexidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: FLUoxetine may increase the serum concentration of Lomitapide.  Management: Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half with concurrent fluoxetine; the lomitapide dose may then be increased to a max adult dose of 30 mg/day (patients on lomitapide 5 mg/day may continue that dose).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maprotiline: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Maprotiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Metoclopramide.  Management: For gastroparesis: reduce metoclopramide dose to 5mg 4 times/day and limit to 20mg/day; nasal spray not recommended.  For GERD: reduce metoclopramide dose to 5mg 4 times/day or to 10mg 3 times/day and limit to 30mg/day. Monitor for toxicity when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nebivolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MMDL metabolite may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Nicergoline. Specifically, concentrations of the MDL metabolite may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: FLUoxetine may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: FLUoxetine may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Oliceridine. Management: Monitor for increased opioid effects (eg, respiratory depression, sedation) and for serotonin syndrome/serotonin toxicity when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omeprazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Omeprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may diminish the therapeutic effect of Opioid Agonists (metabolized by CYP3A4 and CYP2D6). Management: Monitor for decreased therapeutic response (eg, analgesia) and opioid withdrawal when coadministered with SSRIs that strongly inhibit CYP2D6. Additionally, monitor for serotonin syndrome/serotonin toxicity if these drugs are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: FLUoxetine may enhance the antiplatelet effect of PARoxetine. FLUoxetine may enhance the serotonergic effect of PARoxetine. This could result in serotonin syndrome. FLUoxetine may increase the serum concentration of PARoxetine. PARoxetine may increase the serum concentration of FLUoxetine.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes), bleeding, and increased SSRI toxicities when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perhexiline: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Perphenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Pitolisant.  Management: Reduce the pitolisant dose by 50% if a strong CYP2D6 inhibitor is initiated. For patients receiving strong CYP2D6 inhibitors, initiate pitolisant at 8.9 mg once daily and increase after 7 days to a maximum of 17.8 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primaquine: CYP2D6 Inhibitors (Strong) may diminish the therapeutic effect of Primaquine. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Primaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Proguanil: CYP2C19 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Proguanil. CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Proguanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Rasagiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP2D6 Inhibitors (Strong) may increase the serum concentration of RisperiDONE.  Management: Careful monitoring for risperidone toxicities and possible dose adjustment are recommended when combined with strong CYP2D6 inhibitors. See full interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Use the lowest effective dose of SSRIs in patients treated with safinamide and monitor for signs and symptoms of serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of other Selective Serotonin Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of other Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Selegiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Serotonin/Norepinephrine Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Sertindole.  Management: Consider alternatives to this combination when possible. If combined, consider using lower doses of sertindole and monitor the ECG closely for evidence of QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, strong CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Avoid concurrent use of strong CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with a reduced clinical effectiveness of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased.  Management: Limit the tetrabenazine dose to 50 mg per day (25 mg per single dose) in patients taking strong CYP2D6 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: FLUoxetine may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Ophthalmic): CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Ophthalmic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Systemic): CYP2D6 Inhibitors (Strong) may increase the serum concentration of Timolol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Tolterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the adverse/toxic effect of TraMADol. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may diminish the therapeutic effect of TraMADol.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes), seizures, and decreased tramadol efficacy when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: FLUoxetine may enhance the serotonergic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP2D6 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Valbenazine.  Management: Reduce valbenazine dose to 40 mg once daily when combined with a strong CYP2D6 inhibitor. Monitor for increased valbenazine effects/toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venlafaxine: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). Venlafaxine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors). This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may decrease serum concentrations of the active metabolite(s) of Venlafaxine. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Venlafaxine. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the antiplatelet effect of Vortioxetine. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may enhance the serotonergic effect of Vortioxetine. This could result in serotonin syndrome. Selective Serotonin Reuptake Inhibitors (Strong CYP2D6 Inhibitors) may increase the serum concentration of Vortioxetine.  Management: Consider alternatives to this drug combination. If combined, reduce the vortioxetine dose by half and monitor for signs and symptoms of bleeding and serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, autonomic instability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP2D6 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54460542"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Fluoxetine is approved for the treatment of unipolar major depressive disorder. If treatment for major depressive disorder is initiated for the first time in patients planning to become pregnant, agents other than fluoxetine are preferred (use of fluoxetine is not preferred for use during pregnancy) (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Fluoxetine is also used off label for the treatment of premenstrual dysphoric disorder. For patients attempting to conceive, symptom onset dosing may be beneficial to minimize potential fetal exposure (Ismaili 2016; Lanza di Scalea 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Selective serotonin reuptake inhibitors (SSRIs) may be associated with male and female treatment-emergent sexual dysfunction (Coskuner 2018; WFSBP [Bauer 2013]). Decreased libido and anorgasmia have been reported in females; abnormal ejaculation, decreased libido, and impotence have been reported in males with fluoxetine use. This may also be a manifestation of the psychiatric disorder. The actual risk associated with fluoxetine is not known. SSRI-related sexual dysfunction may resolve with dose reduction or discontinuation of the SSRI; in some cases, sexual dysfunction may persist once therapy is discontinued (Coskuner 2018; Jing 2016; Waldinger 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Fluoxetine is used off label for the treatment of premature ejaculation. Although data is limited, some studies have shown SSRIs may impair the motility of spermatozoa, therefore use of other treatments may be preferred in patients planning to father a child (Althof 2014; Siroosbakht 2019; Sylvester 2019).</p></div>
<div class="block pri drugH1Div" id="F172698"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Fluoxetine and its metabolite cross the placenta. Fluoxetine is cleared slowly by the newborn (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, selective serotonin reuptake inhibitors (SSRIs) have been evaluated extensively in pregnant patients. Studies focusing on newborn outcomes following first trimester exposure often have inconsistent results due to differences in study design and confounders such as maternal disease and social factors. An increased risk of adverse cardiovascular events following in utero exposure to fluoxetine has been observed in some studies; however, a causal relationship has not been established (Anderson 2020; Biffi 2020; Fitton 2020; Reefhuis 2015; Womersley 2017).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse effects in the newborn following SSRI exposure late in the third trimester can include apnea, constant crying, cyanosis, feeding difficulty, hyperreflexia, hypo- or hypertonia, hypoglycemia, irritability, jitteriness, respiratory distress, seizures, temperature instability, tremor, and vomiting. Prolonged hospitalization, respiratory support, or tube feedings may be required. Symptoms may be due to the toxicity of the SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn has been reported with SSRI exposure; although the absolute risk is small, monitoring of infants exposed to SSRIs late in pregnancy is recommended (Masarwa 2019; Ng 2019). The long-term effects of in utero SSRI exposure on infant neurodevelopment and behavior are not known (CANMAT [MacQueen 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic parameters of fluoxetine may be altered (Heikkinen 2003; Hostetter 2000; Kim 2006; Sit 2010). However, dose adjustments may only be needed if symptoms recur or worsen during pregnancy. Close clinical monitoring as pregnancy progresses and therapeutic drug monitoring to detect patterns of changing plasma concentrations is recommended to assist dose adjustment when needed. If dosing is increased during pregnancy, a gradual taper to the prepregnancy range should be done postpartum (Betcher 2020; Schoretsanitis 2020; Sit 2010).</p>
<p style="text-indent:0em;margin-top:2em;">If treatment for major depressive disorder is initiated for the first time during pregnancy, fluoxetine is not one of the preferred SSRIs (CANMAT [MacQueen 2016]; Larsen 2015; WFSBP [Bauer 2013]). If pregnancy occurs during fluoxetine therapy, a change in treatment is only recommended if it can be safely done in relation to maternal disease (Larsen 2015). Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) as compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antidepressant medications is ongoing. Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants. Pregnant patients 18 to 45 years of age or their health care providers may contact the registry to enroll; enrollment should be done as early in pregnancy as possible (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/).</p></div>
<div class="block brc drugH1Div" id="F172699"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Fluoxetine and its active metabolite (norfluoxetine) are present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Information related to the presence of fluoxetine in breast milk is available from multiple studies. The relative infant dose (RID) of fluoxetine has been calculated in review articles to be &lt;12% of the weight adjusted maternal dose (Berle 2011; Orsolini 2015); RIDs up to 20% have also been located (Pogliani 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">- In one review, the RID of fluoxetine was calculated using pooled data from 149 mother/infant pairs providing an estimated daily infant dose via breast milk of 0.14 mg/day. The maternal dose and actual breast milk concentrations for the calculation were not provided. Infant plasma concentrations were up to 80% of those in the maternal plasma (Berle 2011).</p>
<p style="text-indent:-2em;margin-left:4em;">- A second review included information from 280 cases; maternal daily doses of fluoxetine were 10 to 80 mg/day. The highest breast milk concentrations of fluoxetine presented were 17 to 293 ng/mL following maternal doses of 20 to 40 mg/day from a study of 11 women 2 to 23 weeks postpartum, providing a RID of 6.5%; norfluoxetine was also present in breast milk. Fluoxetine and norfluoxetine were detected in the serum of some infants (Orsolini 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">- A study published since these reviews reports a fluoxetine RID of 20%, following a maternal dose of 20 mg/day taken by one woman throughout pregnancy and continuing postpartum; sampling occurred within 7 days after delivery (fluoxetine concentrations 323.3 ng/mL [breast milk]; 216.8 ng/mL [maternal serum]) (Pogliani 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">- Concentrations of norfluoxetine in breast milk should also be considered. In a study of 19 women (20 infants), maternal and infant serum samples were obtained 5 to 34 weeks after delivery following maternal use of fluoxetine 10 to 60 mg/day. Fluoxetine was present in 30% of infant serum samples (range: &lt;1 to 84 ng/mL) and norfluoxetine was present in 85% (range: &lt;1 to 265 ng/mL). Breast milk was sampled in 9 cases. Peak breast milk concentrations of fluoxetine and norfluoxetine occurred 8 hours after the maternal dose and correlated highly with infant serum concentrations for norfluoxetine. The highest milk concentration of fluoxetine in this study was 235 ng/mL and the same mother also had the highest norfluoxetine milk concentration (222 ng/mL). These concentrations were obtained following a maternal dose of 40 mg/day. Women with serum concentrations of fluoxetine plus norfluoxetine &lt;150 ng/mL had infants with low (&lt;5 ng/mL) to nondetectable serum concentrations (Hendrick 2001).</p>
<p style="text-indent:-2em;margin-left:4em;">- Based on available data, infants exposed to fluoxetine via breast milk are more likely to have elevated plasma concentrations in comparison to those exposed to other selective serotonin reuptake inhibitors (SSRIs) (Weissman 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">- In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000); however, some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015). When an RID is &gt;25%, breastfeeding should generally be avoided (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">Adverse events in the breastfeeding infant have been reported following maternal use of fluoxetine, including agitation, irritability, poor feeding, and poor weight gain; crying, sleep disturbance, vomiting, and watery stools have also been reported (Kristensen 1999; Lester 1993). Infants exposed to an SSRI via breast milk should be monitored for irritability and changes in sleep, feeding patterns, and behavior, as well as growth and development (ABM [Sriraman 2015]; Sachs 2013; Weissman 2004; WFSBP [Bauer 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Maternal use of an SSRI during pregnancy may cause delayed lactogenesis (Marshall 2010), however the underlying maternal illness may also influence this outcome (Grzeskowiak 2018). Untreated severe or chronic depression in the postpartum period also has negative effects on the mother and the infant (Slomian 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during fluoxetine therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p>
<p style="text-indent:-2em;margin-left:2em;">Psychotherapy or other nonmedication therapies are recommended for the initial treatment of mild depression in breastfeeding patients; antidepressant medication is recommended when psychotherapy is not an option or symptoms are moderate to severe. If a specific SSRI was used effectively during pregnancy, it can be continued while breastfeeding if no contraindications exist (ABM [Sriraman 2015]).</p>
<p style="text-indent:-2em;margin-left:2em;">When first initiating an antidepressant in a breastfeeding patient, agents other than fluoxetine are preferred (ABM [Sriraman 2015]; CANMAT [MacQueen 2016]; Larsen 2015).</p></div>
<div class="block mop drugH1Div" id="F172683"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Serum sodium in at-risk populations (as clinically indicated); blood glucose (for diabetic patients); liver and renal function (baseline and as clinically indicated); ECG assessment and periodic monitoring in patients with risk factors for QT prolongation and ventricular arrhythmia; closely monitor patients for depression, clinical worsening, suicidality, or unusual changes in behavior (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania, social functioning), particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); signs/symptoms of serotonin syndrome, such as mental status changes (eg, agitation, hallucinations, delirium, coma), autonomic instability (eg, tachycardia, labile BP, diaphoresis), neuromuscular changes (eg, tremor, rigidity, myoclonus), GI symptoms (eg, nausea, vomiting, diarrhea), and/or seizures; akathisia; sleep status</p></div>
<div class="block rer drugH1Div" id="F172687"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Therapeutic levels have not been well established.</p>
<p style="text-indent:-2em;margin-left:2em;">Therapeutic: Fluoxetine: 100 to 800 ng/mL (SI: 289 to 2,314 nmol/L); Norfluoxetine: 100 to 600 ng/mL (SI: 289 to 1,735 nmol/L)</p>
<p style="text-indent:-2em;margin-left:2em;">Toxic: Fluoxetine plus norfluoxetine: &gt;2,000 ng/mL</p></div>
<div class="block pha drugH1Div" id="F172673"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits CNS neuron serotonin reuptake; minimal or no effect on reuptake of norepinephrine or dopamine; does not significantly bind to alpha-adrenergic, histamine, or cholinergic receptors</p></div>
<div class="block phk drugH1Div" id="F172693"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Anxiety disorders (generalized anxiety, panic, obsessive-compulsive disorder, posttraumatic stress disorder): Initial effects may be observed within 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Issari 2016; Varigonda 2016; WFSBP [Bandelow 2023a]); some experts suggest up to 12 weeks of treatment may be necessary for response, particularly in patients with obsessive-compulsive disorder and posttraumatic stress disorder (BAP [Baldwin 2014]; Katzman 2014; WFSBP [Bandelow 2023a]; WFSBP [Bandelow 2023b]).</p>
<p style="text-indent:-2em;margin-left:4em;">Body dysmorphic disorder: Initial effects may be observed within 2 weeks; some experts suggest up to 12 to 16 weeks of treatment may be necessary for response in some patients (Phillips 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009; Taylor 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Premenstrual dysphoric disorder: Initial effects may be observed within the first few days of treatment, with response at the first menstrual cycle of treatment (ISPMD [Nevatte 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Well absorbed; delayed 1 to 2 hours with weekly formulation</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 12 to 43 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 95% to albumin and alpha<sub>1</sub> glycoprotein</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, via CYP2C19 and 2D6, to norfluoxetine (activity equal to fluoxetine)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Adults:</p>
<p style="text-indent:-2em;margin-left:4em;">Parent drug: 1 to 3 days (acute), 4 to 6 days (chronic), 7.6 days (cirrhosis)</p>
<p style="text-indent:-2em;margin-left:4em;">Metabolite (norfluoxetine): 9.3 days (range: 4 to 16 days), 12 days (cirrhosis)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 6 to 8 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (10% as norfluoxetine, 2.5% to 5% as fluoxetine)</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Weekly formulation results in greater fluctuations between peak and trough concentrations of fluoxetine and norfluoxetine compared to once-daily dosing (24% daily/164% weekly; 17% daily/43% weekly, respectively). Trough concentrations are 76% lower for fluoxetine and 47% lower for norfluoxetine than the concentrations maintained by 20 mg once-daily dosing. Steady-state fluoxetine concentrations are ~50% lower following the once-weekly regimen compared to 20 mg once daily. Average steady-state concentrations of once-daily dosing were highest in children ages 6 to &lt;13 (fluoxetine 171 ng/mL; norfluoxetine 195 ng/mL), followed by adolescents ages 13 to &lt;18 (fluoxetine 86 ng/mL; norfluoxetine 113 ng/mL); concentrations were considered to be within the ranges reported in adults (fluoxetine 91 to 302 ng/mL; norfluoxetine 72 to 258 ng/mL).</p></div>
<div class="block phksp drugH1Div" id="F51192585"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: The half-life for fluoxetine and norfluoxetine is prolonged. Elimination half-life increased from 2.2 days in controls to 6.6 days and clearance decreased by 50% following a single dose of fluoxetine in patients with stable alcoholic cirrhosis (Mullish 2014; Schenker 1988).</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Average steady-state fluoxetine serum concentrations in children (n=10; 6 to &lt;13 years of age) were 2-fold higher than in adolescents (n=11; 13 to &lt;18 years of age); all patients received 20 mg/day; average steady-state norfluoxetine serum concentrations were 1.5-fold higher in the children compared with adolescents; differences in weight almost entirely explained the differences in serum concentrations.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F172701"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Flozak | Fluneurin | Fluoxone | Fluran | Fluxetyl | Fluzyn | Prozac | Salipax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alental | Animex-on | Anzolden | Captaton | Eburnate | Equilibrane | Faboxetina | Falimus | Felixina | Fibrotina | Fiorot | Fluopiram | Fluoxetina Cevallos | Fluoxetina fabra | Fluoxetina northia | Fluoxetina teva | Fluoxiram | Foxetin | Lapsus | Mitilase | Nervosal | Neupax | Pridamos | Prozac | Saurat | Xetna</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Felicium | Floccin | Fluctine | Fluoxetin 1a pharma | Fluoxetin 1a pharma gmbh | Fluoxetin arcana | Fluoxetin G L | Fluoxetin genericon pharma | Fluoxibene | Flux | Fluxil | Fluxomed | Mutan | Positivum</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo fluoxetine | Auscap | Blooms the chemist fluoxetine | Btc fluoxetine | Cm fluoxetine | Dbl fluoxetine | Erocap | Fluohexal | Fluotex | Fluoxebell | Fluoxetine | Fluoxetine an | Fluoxetine apotex | Fluoxetine as | Fluoxetine ascent | Fluoxetine Ga | Fluoxetine Generichealth | Fluoxetine mlabs | Fluoxetine ps | Fluoxetine Rbx | Fluoxetine sandoz | Fluoxetine-bc | Fluoxetine-dp | Lovan | Noumed fluoxetine | Pharmacor fluoxetine | Prozac | Sbpa fluoxetine | Tw fluoxetine | Zactin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Depil | Modipran | Nodep | Nodepress | Prodep | Prolert | Prozac</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Docfluoxetine | Fluox | Fluoxemed | Fluoxetine aurobindo | Fluoxetine eg | Fluoxetine eurogenerics | Fluoxetine merck-generics | Fluoxetine sandoz | Fluoxetine teva generics belgium | Fluoxetine Topgen | Fluoxetop | Fontex | Prosimed | Prozac</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Prozac</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Biflox | Biozac | Deprexit | Fluoxetin | Fluval | Prozac | Ranflutin | Sofluxen</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Cloridrato de fluoxetina | Daforin | Depoflox | Deprax | Depress | Detaque | Eufor | Fluox | Fluoxetin | Fluoxetina | Fluxene | Neo fluoxetin | Nortec | Prozac | Prozac durapac | Prozen | Psiquial | Verotina | Zyfloxin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fluctine | Fluocim | Fluox-basan | Fluoxetin actavis | Fluoxetin Axapharm | Fluoxetin Cimex | Fluoxetin helvepharm | Fluoxetin Helvepharma | Fluoxetin Sandoz | Fluoxetin sandoz eco | Fluoxetin spirig | Fluoxetin Streuli | Fluoxetin Teva | Fluoxetin zentiva | Fluoxetin-Dista | Fluoxetine Winthrop | Fluoxetine-mepha | Fluoxifar | Flusol | Prozac</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Calmz | Fluoxetina | Fluoxetine Merinal</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Actan | Alentol | Anisimol | Clinium | Dominium | Fluoxetina | Fluseren | Pragmaten | Prozac | Sostac | Tremafarm | Ultiflox</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao mai lun | Apo fluoxetine | Fluoxetine | Ju li neng | Kai ke | Prozac | Yi wei zhi | You ke | Zactin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Ansidep | Ansilan | Cresptor | Deprexin | Fluopres | Fluoxetina | Fluoxetina mk | Flutin | Fluxene | Moltoben | Pragmaten | Pressetina | Prozac | Xetil | Xetinax | Zepax</span>;</li>
<li>
<span class="countryCode">(CR)</span> <span class="country">Costa Rica</span><span class="countrySeparator">: </span><span class="drugName">Xetina raven</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo fluoxetine | Defluox | Deprenon | Deprex | Floxet | Flumirex | Fluoxetin | Fluoxetine aurobindo | Fluoxetine vitabalans | Fluoxetine-mepha | Fluoxin | Fluxonil | Fluzak | Magrilan | Portal | Prozac | Salipax</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Flucti-nerton | Fluctin | Fluctine | Fluneurin | Fluox | Fluox-puren | Fluoxa | Fluoxe-Q | Fluoxelich | Fluoxemerck | Fluoxetin | Fluoxetin 1a pharma | Fluoxetin actavis | Fluoxetin beta | Fluoxetin CT | Fluoxetin Dura | Fluoxetin ksk | Fluoxetin micro labs | Fluoxetin Ratiopharm | Fluoxetin rph | Fluoxetin Sandoz | Fluoxetin Stada | Fluoxetin Teva | Fluoxetin Vitabalans | Fluoxetin-biomo | Fluoxgamma | Fluxet | Fysionorm | Motivone | Prozac</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Fluoxetin alpharma | Flutin | Folizol</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Actan | Cymaflox | Depress | Deprifel | Deturben | Equiflox | Flocefran | Fluoxetina | Fluoxetina mk | Fluoxil | Flutinax | Fluxadir | Fluxal | Foxetin | Hapilux | Moltoben | Neolzina | Prozac | Rowexetina | Siquial | Tiflum</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Actan | Dominium | Flouxac | Fluoxac | Fluoxepharm | Fluoxetina | Fluxiten | Luminal | Neupax | Pragmaten | Proxetina | Prozac | Rowexetina | Salipax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Deprenon | Deprex | Deprimax | Fluoxetine | Fluoxetine vitabalans | Fluval | Flux | Framex | Magrilan | Nycoflox | Prozac | Salipax | Seronil</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Alzac | Depezac | Depreban | Durazac | Elevamood | Fiesto | Florosin | Fluozac | Flutin | Fluxotine | Octozac | Philozac | Prozac</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Adofen | Astrin | Fluoxetina alacan | Fluoxetina almus | Fluoxetina alter | Fluoxetina apotex | Fluoxetina Aristo | Fluoxetina asol | Fluoxetina aurobindo | Fluoxetina aurovitas | Fluoxetina bayvit | Fluoxetina belmac | Fluoxetina bexal | Fluoxetina cinfa | Fluoxetina combino | Fluoxetina cuve | Fluoxetina davur | Fluoxetina Diasa | Fluoxetina edigen | Fluoxetina esteve | Fluoxetina ferrer | Fluoxetina grapa | Fluoxetina kern | Fluoxetina korhispana | Fluoxetina lareq | Fluoxetina lasa | Fluoxetina mabo | Fluoxetina merck | Fluoxetina normon | Fluoxetina ranbaxy | Fluoxetina rimafar | Fluoxetina rubio | Fluoxetina sandoz | Fluoxetina Tarbis | Fluoxetina vir | Lecimar | Luramon | Nodepe | Prozac | Reneuron</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Fluoxetine</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fluoksetiini ennapharma | Fluoxal | Fluoxetin generics | Fluoxetin Sandoz | Fluoxetine ranbaxy | Fluoxetine stada | Fluoxetinevitabalans | Fluxantin | Fontex | Seromex | Seronil</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fluoxetine | Fluoxetine almus | Fluoxetine Alter | Fluoxetine arrow | Fluoxetine biogaran | Fluoxetine Bouchara Recordati | Fluoxetine cristers | Fluoxetine evolugen | Fluoxetine g gam | Fluoxetine GNR | Fluoxetine Intas | Fluoxetine irex | Fluoxetine Isomed | Fluoxetine ivax | Fluoxetine merck | Fluoxetine phr | Fluoxetine Qualimed | Fluoxetine ranbaxy | Fluoxetine ratiopharm | Fluoxetine rpg | Fluoxetine teva | Fluoxetine zydus | Prozac</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Felicium | Fluoxetine | Fluoxetine almus | Fluoxetine arrow | Fluoxetine cox | Fluoxetine kent | Fluoxetine sandoz | Oxactin | Prozac | Prozep | Prozit | Ranflutin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Dagrilan | Dinalexin | Exostrept | Flonital | Fluoxetine | Fluoxetine/mylan | Fluxadir | Fokeston | Hapilux | Ladose | Orthon | Sartuzin | Sofelin | Stephadilat S | Stressless | Thiramil | Zinovat</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Altazac | Apo fluoxetine | Cp-Fluoxet | Dawnex | Deprexin | Flunil | Fluoxetine | Fluxetin | Fluxil | Magrilan | Nopres | Pms fluoxetine | Prozac | Qualisac | Sartuzin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fluval | Portal | Prozac</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Apo fluoxetin | Deprexin | Fefluzin | Floxet | Fluoxetine vitabalans | Huma-fluoxetin | Portal | Praxin | Prozac</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Andep | Ansi | Antiprestin | Courage | Deprezac | Deproz | Elizac | Fluoxetine HCL | Foransi | Kalxetin | Lodep | Nopres | Noxetine | Oxipres | Prozac | Zac</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Affex | Bellzac | Biozac | Fluoxetine | Fluzac | Gerozac | Norzac | Prozac | Prozamel | Prozatan | Prozit</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Affectine | Flutine | Prizma | Prozac</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Barozac | Cadflo | Cozac | Cozac t | Cyclotin | Dawnex | Defutin | Deploid | Depnil | Depoxit | Depten | Depzac | Exiten | F tin | Fadep | Faxtin | Floatin | Flonol | Flood | Floxin | Floxistar | Floxy | Flucap | Fluchem | Flucon | Fludac | Fludawn | Fludep | Fluex | Flugen | Flumeg | Flumod | Flumusa 20 | Flunat | Flunil | Fluoxet | Fluoxetine | Fluriv | Flutee | Flutex | Flutin | Flutine | Flutinol | Flutop | Flutop la | Flux | Fluxal | Fluxater | Fluze | Fuox | Halonet | Latin | Loftil | Lutine | M.codep | Maxitin | Mentol | Neurozac | Noc | Nodep | Normatine | Nuzac | Oxefil | Oxetin | Persona | Platin | Prodac | Prodep | Pronil | Salidep | Serodep | Trizac | Vetodep | Zedep | Zexto</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Serol</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Azur | Clexiclor | Cloriflox | Deprexen | Diesan | Flotina | Fluoxeren | Fluoxetina | Fluoxetina Accord | Fluoxetina almus | Fluoxetina alter | Fluoxetina angenerico | Fluoxetina big | Fluoxetina doc | Fluoxetina drm | Fluoxetina eg | Profelix | Prozac | Xeredien</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Anxetin | Diesan | Fluocim | Fluxil | Magrilan | Oxetine | Proxetine | Prozac | Rozax | Salipax</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Deprozet | Fludac | Flunil | Fluxil | Modipran | Prodep | Prozac | Serozac</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Antipres | Antipress | Barozac | Danatec | Depren | Deprexin | Difmax | Difxetine | Floctin | Floctine | Flonin | Flotin | Floxetine | Flugen | Fluneurin | Fluox | Fluoxetine | Fluoxetine hcl daewha | Flutin | Fluxetin | Fluxetine | Fonoxetin | Foxetin | Foxtine | Frictin | Fropine | Fucetin | Fulxetin | Furotin | Furoxetine | Furuzac | Fusetin | Fuxetine | Hanall fluoxetine hcl | Hanpro | I xetin | Kukje fluoxetine | Lanclic | Locetin | Lorang | Lotine | Loxetin | Lucetin | Nanotec | Neurozac | Nobsetine | Norzac | Obeflu | Obetine | Oxetine | Oxigreen | Oxygreen | Pms fluoxetine | Ponoxetine | Prajac | Procetin | Proctin | Propine DR5 | Proren | Prozac | Psylotine | Ranclik | Rocetan | Serotine | Seroxetine | Serozac | Sixetine | Sleexetine | Unizac | Urozac | Welfit | Wexetine | Xelectin | Xezac | Yungjin fluoxetine | Zerozac</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Anxetin | Flozak | Fluneurin | Fluxetyl | Prozac | Salipax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fluocim | Fluoxetina belmac | Fluoxetine | Fluoxetine biogaran | Fluoxone Divule | Flutin | Neanxetin | Plazeron | Proxetin | Prozac | Rosal | Sartuzin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Apo fluoxetine | Deprexetin | Deprimaks | Floxet | Fluoxetine | Fluoxetine-mepha | Fluval | Flux | Framex | Magrilan | Nycoflox | Prozac | Salipax</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Docfluoxetine | Fluoxetin Ratiopharm | Fluoxetine | Fontex | Prozac</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Deprenon | Deprex | Deprimax | Floxet | Fluaxen | Fluoxetine | Fluoxetine vitabalans | Fluoxetine-mepha | Fluoxetini | Flux | Framex | Magrilan | Nycoflox | Prozac | Salipax | Seronil</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Fluctine | Fluoxet | Fluzoft | Prozac | Serdep | Tuneluz | Vyoxet</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Fluoxetine-mepha | Salipax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Altoprezol | Aniup | Antynax | Aponeusak | Auroken | Axtin | Bixilan | F exina | Farmaxetina | Flocet | Florexal | Fluctine | Fluneurin | Fluoxac | Fluoxetina | Fluoxetina g.i | Fluoxetina gi | Fluoxetina protein | Fluoxetine | Flutinax | Genozac | Indozul | Laegaudin | Lebensart | Ovisen | Pisaurit | Prodep | Prozac | Quanilene | Regultron | Siquial | Teczac | Ulmely | Vicsel | Xenacan | Zatin | Zertix</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Anzack | Dawnex | FLEXIN | Fluovex | Fluran | Fluxetil | Provatine | Prozac | Salipax | Uxetine</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Seroxetine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Fluoxetine | Fluoxetine aurobindo | Fluoxetine CF | Fluoxetine PCH | Fluoxetine ratiopharm | Prozac</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fluoxetin | Fluoxetine orion | Fluoxetine vitabalans | Fontex | Nycoflox</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow Fluoxetine | Fluotex | Fluox | Lovan | Plinzene | Prozac</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Evorex</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Dawnex | Depricor | Emozac | Fluoxetina | Fluran | Fluxentac | Neolzina | Ofluoxet | Prozac | Prozac durapac | Sostac</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Adep | Adepssir | Deprizac | Magrilan | Motivest | Neuxetin | Oxedep | Prodin | Prozac</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Advance | Alert | Astovas | Azene | Besquil | Cyconil | Dep-nil | Depex | Deplow | Deporex | Depranil | Deprezac | Depricap | Deprox | Deptin | Duzest | Extine | F tine | Faxetine | Felix | Flectin | Flit | Flotin | Flouxac | Floxac | Floxitol | Fluoxe-Scot | Flute | Flutin | Flux | Fluxafin | Fluxil | Fluxit | Foxatin | Freezak | Futine | Galaxy | Geoxit | Modipran | Neozac | Optimist | Oxetin | Phloxetin | Prolert | Prolyd | Prome | Prozac | Prozyn | Reset | Rize | Rozax | Sero ze | Seronil | Serratol | Tepaxor | Traxectin | Ufrex | Vonder | Xetin | Xotin | Zacpro | Zauxit</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Andepin | Bioxetin | Deprexetin | Fluoksetyna | Fluoksetyna Egis | Fluoxetin | Fluoxetine aurovitas | Fluoxetine vitabalans | Fluxemed | Prozac | Salipax | Seronil | Xetiran</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Fluoxetine | Fluoxetine HCL | Prozac | Sarafem</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Digassim | Fluoxetina | Fluoxetina Accord | Fluoxetina apceuticals | Fluoxetina aurovitas | Fluoxetina azevedos | Fluoxetina Daquimed | Fluoxetina odipe | Fluoxetina tuneluz | Fluoxetine-mepha | Fluxin | Nodepe | Prozac | Psipax | Salipax | Selectus | Tuneluz</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Actan | Conexine | Confium | Eximius | Fluoxetina chile | Fluoxetina dallas | Fluoxetina genfar | Fluoxetina la sante | Fluoxetina mintlab | Fluoxetina phi | Fluoxetina ragusa | Frendix | Plenocer | Pragmaten | Somatin | Sostac | Tonovital</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Anextin | Evorex | Flozak | Flunurine | Flutin | Fluzyn | Linz | Proxetine | Prozac | Rozax | Salipax</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Anxetin | Floxet | Fluocim | Fluohexal | Fluoxetin lph | Fluoxetine | Fluoxin | Fluran | Fluval | Fluxonil</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Apo fluoxetin | Apo fluoxetine | Deprenon | Floxet | Flunisan | Fluoxetine | Fluoxetine canon | Fluoxetine hexal | Fluoxetine lannacher | Fluval | Fluxonil | Framex | Portal | Prodep | Profluzac | Prozac</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Anxetin | Flozak | Fluoxetin hexal | Fluxetyl | Fluzyn | Linz | Oxetine | Pms fluoxetine | Prozac | Salipax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fluoxetin Bioglan | Fluoxetin Mylan | Fluoxetin Ratiopharm | Fluoxetin Sandoz | Fluoxetin Selena | Fluoxetin Stada | Fluoxetin Teva | Fluoxetine accord | Fluoxetine orion | Fluoxetine vitabalans | Fluxantin | Fontex | Fontex Basal</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo fluoxetine | Deprexin | Fluoxetine | Fluxetil | Fluxil | Foxtin | Magrilan | Proctin | Prozac | Zactin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Fluoksetin Vitabalans | Fluval | Portal | Prozac | Salipax</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Deprenon | Deprex | Floxet | Fluoxetine vitabalans | Fluval | Fluxonil | Hapilux | Magrilan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Actisac | Anzac | Britezac | Cefu | Deproxin | F Zac | Flulox | Flumed | Fluoxan | Fluoxetine | Fluoxine | Flusac | Flutine | Fluxetil | Fluxetin | Fluzac | Fluzac-20 | Foxetin | Fulox | Hapilux | Loxetine | Magrilan | Oxetine | Oxsac | Prodep | Proxetin | Prozac | Staroxtin | Unprozy | Upsac | Xelotin | Xetin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Anxetin | Dinalexin | Prozac | Rosal | Serotyl</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Depreks | Depset | Florak | Foxeteva | Fulsac | Loksetin | Prozac | Seronil | Zedprex</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Apo fluoxetine | Floxt | Fluoxetin | Fluoxetine | Fluronin | Flux | Fluxen | Juxac | Kinxetine | Prozac | Prozac durapac | Seronil | Serotec | Sinzac | U-Zet | Uxetine | Zactin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fluoxetin Kmp | Fluoxetine | Flutisal | Fluxen | Framex | Portal | Prodep | Prozac</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Fluoxiren | Magrilan | Nuzac</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Depreless | Floxet | Fluodep | Fluoxetina | Fluoxetina Szabo | Foxetin | Luserpal | Mitilase | Neupax | Vidacil</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anoxen | Antipres | Fluoxetina | Fluran | Fluzac | Prozac | Psiquial</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Fluotin | Oxeflu</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">A L Fluoxetine | Apo fluoxetine | Deprozan | Fluoxetine | Fluoxetine Actor | Fluoxitine unimed | Lilly-fluoxetine | Lorien | Micro Fluoxetine | Nuzak | Prohexal | Prolax | Prozac | Ranflocs | Rezak | Rolab-fluoxetine | Sanzur | Trizac</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Fludac | Prozac</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Dawnex | Oxedep</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26082973">
<a name="26082973"></a>Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database. <i>J Clin Psychopharmacol</i>. 2015;35(4):382-388. doi:10.1097/JCP.0000000000000344<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/26082973/pubmed" id="26082973" target="_blank">26082973</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. <i>Obstet Gynecol</i>. 2008;111(4):1001‐1020. doi:10.1097/AOG.0b013e31816fd910<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30296343">
<a name="30296343"></a>Agrawal R, Almoghrabi A, Attar BM, Gandhi S. Fluoxetine-induced Stevens-Johnson syndrome and liver injury. <i>J Clin Pharm Ther</i>. 2019;44(1):115-118. doi:10.1111/jcpt.12760<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30296343/pubmed" id="30296343" target="_blank">30296343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1926918">
<a name="1926918"></a>Ahmad S. Fluoxetine and glaucoma. <i>DICP</i>. 1991;25(4):436. doi:10.1177/106002809102500422<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/1926918/pubmed" id="1926918" target="_blank">1926918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25356302">
<a name="25356302"></a>Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). <i>Sex Med</i>. 2014;2(2):60-90. doi:10.1002/sm2.28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25356302/pubmed" id="25356302" target="_blank">25356302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22176943">
<a name="22176943"></a>American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry.</i> 2012;51(1):98-113. doi:10.1016/j.jaac.2011.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/22176943/pubmed" id="22176943" target="_blank">22176943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11665545">
<a name="11665545"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with borderline personality disorder. American Psychiatric Association. <i>Am J Psychiatry</i>. 2001;158(suppl 10):1-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11665545/pubmed" id="11665545" target="_blank">11665545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2009">
<a name="APA.2009"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2nd ed. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed August 2, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2010">
<a name="APA.2010"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf Published October 2010. Accessed June 25, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychological Association (APA). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf. Published February 16, 2019. Accessed April 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32777011">
<a name="32777011"></a>Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. <i>JAMA Psychiatry</i>. 2020;77(12):1246-1255. doi:10.1001/jamapsychiatry.2020.2453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/32777011/pubmed" id="32777011" target="_blank">32777011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190637">
<a name="21190637"></a>Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. <i>J Clin Psychiatry</i>. 2010;71(12):1565-1575. doi:10.4088/JCP.09r05786blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/21190637/pubmed" id="21190637" target="_blank">21190637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811-819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluoxetine.1">
<a name="Fluoxetine.1"></a>APO-Fluoxetine capsules and oral solution [product monograph]. Toronto, Ontario, Canada: Apotex Inc; January 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12444817">
<a name="12444817"></a>Arnold LM, McElroy SL, Hudson JI, Welge JA, Bennett AJ, Keck PE. A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder. <i>J Clin Psychiatry</i>. 2002a;63(11):1028-1033.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12444817/pubmed" id="12444817" target="_blank">12444817</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11893345">
<a name="11893345"></a>Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE Jr. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. <i>Am J Med.</i> 2002b;112(3):191-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11893345/pubmed" id="11893345" target="_blank">11893345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6610522">
<a name="6610522"></a>Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L. Fluoxetine kinetics and protein binding in normal and impaired renal function. <i>Clin Pharmacol Ther</i>. 1984;36(1):138-144. doi:10.1038/clpt.1984.152<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/6610522/pubmed" id="6610522" target="_blank">6610522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23699725">
<a name="23699725"></a>Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Lindenauer PK. Perioperative use of selective serotonin reuptake inhibitors and risks for adverse outcomes of surgery. <i>JAMA Intern Med</i>. 2013;173(12):1075-1081. doi:10.1001/jamainternmed.2013.714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/23699725/pubmed" id="23699725" target="_blank">23699725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23219059">
<a name="23219059"></a>Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. <i>J Affect Disord</i>. 2013;148(1):129-135. doi:10.1016/j.jad.2012.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/23219059/pubmed" id="23219059" target="_blank">23219059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2014;28(5):403-439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023a;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry</i>. 2023b;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22540422">
<a name="22540422"></a>Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. <i>Int J Psychiatry Clin Pract</i>. 2012;16(2):77-84. doi:10.3109/13651501.2012.667114<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/22540422/pubmed" id="22540422" target="_blank">22540422</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18949648">
<a name="18949648"></a>Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. <i>World J Biol Psychiatry</i>. 2008;9(4):248-312. doi:10.1080/15622970802465807<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18949648/pubmed" id="18949648" target="_blank">18949648</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28558366">
<a name="28558366"></a>Barbuti M, Pacchiarotti I, Vieta E, et al. Antidepressant-induced hypomania/mania in patients with major depression: Evidence from the BRIDGE-II-MIX study. <i>J Affect Disord</i>. 2017;219:187-192. doi:10.1016/j.jad.2017.05.035<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28558366/pubmed" id="28558366" target="_blank">28558366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29320378">
<a name="29320378"></a>Barterian JA, Sanchez JM, Magen J, Siroky AK, Mash BL, Carlson JS. An examination of fluoxetine for the treatment of selective mutism using a nonconcurrent multiple-baseline single-case design across 5 cases. <i>J Psychiatr Pract</i>. 2018;24(1):2-14. doi:10.1097/PRA.0000000000000284<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29320378/pubmed" id="29320378" target="_blank">29320378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-induced serotonin syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49-54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, et al; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry.</i> 2015;16(2):76-95. doi:10.3109/15622975.2014.1001786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479080">
<a name="12479080"></a>Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12479080/pubmed" id="12479080" target="_blank">12479080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8002659">
<a name="8002659"></a>Beer K, Albertini J, Medenica M, Busbey S. Fluoxetine-induced hypersensitivity. <i>Arch Dermatol</i>. 1994;130(6):803-804.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8002659/pubmed" id="8002659" target="_blank">8002659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. <i>Drug Saf</i>. 2019;42(8):973-992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9387089">
<a name="9387089"></a>Benazzi F. Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice. <i>J Affect Disord</i>. 1997;46(1):73-77. doi:10.1016/s0165-0327(97)00082-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/9387089/pubmed" id="9387089" target="_blank">9387089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Benedek.2009">
<a name="Benedek.2009"></a>Benedek DM, Friedman MJ, Zatzick D, Ursano RJ. Guideline watch (March 2009): Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd-watch.pdf. Published March 2009. Accessed July 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22299006">
<a name="22299006"></a>Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/22299006/pubmed" id="22299006" target="_blank">22299006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31800350">
<a name="31800350"></a>Betcher HK, Wisner KL. Psychotropic treatment during pregnancy: research synthesis and clinical care principles. <i>J Womens Health (Larchmt)</i>. 2020;29(3):310‐318. doi:10.1089/jwh.2019.7781<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31800350/pubmed" id="31800350" target="_blank">31800350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32135392">
<a name="32135392"></a>Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. <i>J Psychiatr Res</i>. 2020;124:99-108. doi:10.1016/j.jpsychires.2020.02.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/32135392/pubmed" id="32135392" target="_blank">32135392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18808563">
<a name="18808563"></a>Bilen S, Saka M, Ak F, Oztekin N. Persistent dystonia induced by fluoxetine. <i>Intern Med J</i>. 2008;38(8):672-674. doi:10.1111/j.1445-5994.2008.01747.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18808563/pubmed" id="18808563" target="_blank">18808563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12649628">
<a name="12649628"></a>Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2003;42(4):415-423. doi:10.1097/01.CHI.0000037049.04952.9F<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12649628/pubmed" id="12649628" target="_blank">12649628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30081645">
<a name="30081645"></a>Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. <i>Ann Pharmacother</i>. 2019;53(2):186-194. doi:10.1177/1060028018794005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30081645/pubmed" id="30081645" target="_blank">30081645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7961338">
<a name="7961338"></a>Black B, Uhde TW. Treatment of elective mutism with fluoxetine: a double blind, placebo-controlled study. <i>J Am Acad Child Adolesc Psychiatry</i>. 1994;33(7):1000-1006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/7961338/pubmed" id="7961338" target="_blank">7961338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8329791">
<a name="8329791"></a>Blacksten JV, Birt JA. Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine. <i>Ann Pharmacother</i>. 1993;27(6):723-724. doi:10.1177/106002809302700609<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8329791/pubmed" id="8329791" target="_blank">8329791</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9565715">
<a name="9565715"></a>Blumenfield M, Levy NB, Spinowitz B, et al. Fluoxetine in depressed patients on dialysis. <i>Int J Psychiatry Med</i>. 1997;27(1):71-80. doi:10.2190/WQ33-M54T-XN7L-V8MX<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/9565715/pubmed" id="9565715" target="_blank">9565715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bobo.1">
<a name="Bobo.1"></a>Bobo WV, Shelton RC. Bipolar major depression in adults: Efficacy and adverse effects of antidepressants. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1501465">
<a name="1501465"></a>Bost RO, Kemp PM. A possible association between fluoxetine use and suicide. <i>J Anal Toxicol</i>. 1992;16(2):142-145. doi:10.1093/jat/16.2.142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/1501465/pubmed" id="1501465" target="_blank">1501465</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26240751">
<a name="26240751"></a>Bostankolu G, Ayhan Y, Cuhadaroglu F, Yazıcı MK. Serotonin syndrome with a combination of aripiprazole and fluoxetine: a case report. <i>Ther Adv Psychopharmacol</i>. 2015;5(2):138-140. doi:10.1177/2045125314561467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/26240751/pubmed" id="26240751" target="_blank">26240751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24801768">
<a name="24801768"></a>Brunner E, Tohen M, Osuntokun O, Landry J, Thase ME. Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder. <i>Neuropsychopharmacology</i>. 2014;39(11):2549-2559. doi:10.1038/npp.2014.101<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/24801768/pubmed" id="24801768" target="_blank">24801768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30526179">
<a name="30526179"></a>Bruun SB, Petersen I, Kristensen NR, Cronin-Fenton D, Pedersen AB. Selective serotonin reuptake inhibitor use in hip fracture patients: a Danish nationwide prevalence study. <i>Acta Orthop</i>. 2019;90(1):33-39. doi:10.1080/17453674.2018.1543842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30526179/pubmed" id="30526179" target="_blank">30526179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8811276">
<a name="8811276"></a>Burke D, Fanker S. Fluoxetine and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). <i>Aust N Z J Psychiatry</i>. 1996;30(2):295-298. doi:10.3109/00048679609076109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8811276/pubmed" id="8811276" target="_blank">8811276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29099547">
<a name="29099547"></a>Bushnell GA, Compton SN, Dusetzina SB, et al. Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications. <i>J Clin Psychiatry</i>. 2018;79(1):16m11415. doi:10.4088/JCP.16m11415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29099547/pubmed" id="29099547" target="_blank">29099547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10405699">
<a name="10405699"></a>Cai Q, Benson MA, Talbot TJ, et al. Acute hepatitis due to fluoxetine therapy. <i>Mayo Clin Proc</i>. 1999;74(7):692-694. doi:10.4065/74.7.692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10405699/pubmed" id="10405699" target="_blank">10405699</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10501826">
<a name="10501826"></a>Capellà D, Bruguera M, Figueras A, Laporte J. Fluoxetine-induced hepatitis: why is postmarketing surveillance needed?. <i>Eur J Clin Pharmacol</i>. 1999;55(7):545-546. doi:10.1007/s002280050671<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10501826/pubmed" id="10501826" target="_blank">10501826</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27508501">
<a name="27508501"></a>Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. <i>Psychother Psychosom</i>. 2016;85(5):270-288. doi:10.1159/000447034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27508501/pubmed" id="27508501" target="_blank">27508501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Casper.2020">
<a name="Casper.2020"></a>Casper RF, Yonkers KA. Treatment of premenstrual syndrome and premenstrual dysphoric disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28636812">
<a name="28636812"></a>Çetin B, Ergelen M. A case of fluoxetine-induced lower extremity ecchymosis. <i>Prim Care Companion CNS Disord</i>. 2017;19(3):10.4088/PCC.16l02061. Published 2017 Jun 15. doi:10.4088/PCC.16l02061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28636812/pubmed" id="28636812" target="_blank">28636812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20703452">
<a name="20703452"></a>Ceylan ME, Maner F. Long-term use of fluoxetine and multiple skeleton fractures. <i>Eur J Clin Pharmacol</i>. 2010;66(12):1279. doi:10.1007/s00228-010-0880-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/20703452/pubmed" id="20703452" target="_blank">20703452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16467545">
<a name="16467545"></a>Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al, “Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn,” <i>N Engl J Med</i>, 2006, 354(6):579-87.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16467545/pubmed" id="16467545" target="_blank">16467545</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21749836">
<a name="21749836"></a>Chan CT, Chang SS, Yeh EK, Jou LC. Upper gastrointestinal bleeding in an end-stage renal disease patient treated with fluoxetine. <i>Gen Hosp Psychiatry</i>. 2011;33(5):530.e1-530.e5303. doi:10.1016/j.genhosppsych.2011.03.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/21749836/pubmed" id="21749836" target="_blank">21749836</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21557759">
<a name="21557759"></a>Chavant F, Favrelière S, Lafay-Chebassier C, Plazanet C, Pérault-Pochat MC. Memory disorders associated with consumption of drugs: updating through a case/noncase study in the French PharmacoVigilance Database. <i>Br J Clin Pharmacol</i>. 2011;72(6):898-904. doi:10.1111/j.1365-2125.2011.04009.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/21557759/pubmed" id="21557759" target="_blank">21557759</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27135704">
<a name="27135704"></a>Chen HY, Lin CL, Lai SW, Kao CH. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. <i>J Clin Psychiatry</i>. 2016;77(6):e692-e696. doi:10.4088/JCP.15m10038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27135704/pubmed" id="27135704" target="_blank">27135704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29483201">
<a name="29483201"></a>Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and ongoing management. <i>Pediatrics</i>. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29483201/pubmed" id="29483201" target="_blank">29483201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28342338">
<a name="28342338"></a>Chou PH, Chu CS, Chen YH, et al. Antidepressants and risk of cataract development: A population-based, nested case-control study. <i>J Affect Disord</i>. 2017;215:237-244. doi:10.1016/j.jad.2017.03.044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28342338/pubmed" id="28342338" target="_blank">28342338</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10621763">
<a name="10621763"></a>Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR. Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. <i>Br J Psychiatry</i>. 1999;175:17-22. doi:10.1192/bjp.175.1.17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10621763/pubmed" id="10621763" target="_blank">10621763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29463440">
<a name="29463440"></a>Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction?. <i>Sex Med Rev</i>. 2018;6(2):217-223. doi:10.1016/j.sxmr.2017.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29463440/pubmed" id="29463440" target="_blank">29463440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33321509">
<a name="33321509"></a>Costa MA, Gonçalves FG, Tatton-Ramos T, et al Three-arm randomized clinical trial comparing the efficacy of a mindfulness-based intervention with an active comparison group and fluoxetine treatment for adults with generalized anxiety disorder. <i>Psychother Psychosom</i>. 2021;90(4):269-279. doi:10.1159/000511880<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/33321509/pubmed" id="33321509" target="_blank">33321509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8795389">
<a name="8795389"></a>Costagliola C, Mastropasqua L, Steardo L, Testa N. Fluoxetine oral administration increases intraocular pressure. <i>Br J Ophthalmol</i>. 1996;80(7):678. doi:10.1136/bjo.80.7.678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8795389/pubmed" id="8795389" target="_blank">8795389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587851">
<a name="19587851"></a>Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. <i>Curr Neuropharmacol</i>. 2008;6(4):293-310. doi:10.2174/157015908787386104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/19587851/pubmed" id="19587851" target="_blank">19587851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32021688">
<a name="32021688"></a>Couturier J, Isserlin L, Norris M, et al. Canadian practice guidelines for the treatment of children and adolescents with eating disorders. <i>J Eat Disord</i>. 2020;8:4. doi:10.1186/s40337-020-0277-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/32021688/pubmed" id="32021688" target="_blank">32021688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.1">
<a name="Craske.1"></a>Craske M, Bystritsky A. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crone.1">
<a name="Crone.1"></a>Crone C, Fochtmann LJ, Attia E, et al; Guideline Writing Group<i>. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders</i>. 4th ed. American Psychiatric Association; 2023. doi:10.1176/appi.books.9780890424865</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18173768">
<a name="18173768"></a>Csoka AB, Bahrick A, Mehtonen OP. Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors. <i>J Sex Med</i>. 2008;5(1):227-233. doi:10.1111/j.1743-6109.2007.00630.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18173768/pubmed" id="18173768" target="_blank">18173768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16636635">
<a name="16636635"></a>Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. <i>Psychother Psychosom</i>. 2006;75(3):187-188. doi:10.1159/000091777<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16636635/pubmed" id="16636635" target="_blank">16636635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19716436">
<a name="19716436"></a>Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. <i>Clin Gastroenterol Hepatol</i>. 2009;7(12):1314-1321. doi:10.1016/j.cgh.2009.08.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/19716436/pubmed" id="19716436" target="_blank">19716436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15466674">
<a name="15466674"></a>Davidson JR, Foa EB, Huppert JD, et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. <i>Arch Gen Psychiatry.</i> 2004;61(10):1005-1013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15466674/pubmed" id="15466674" target="_blank">15466674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8730028">
<a name="8730028"></a>de Kerviler E, Trédaniel J, Revlon G, et al. Fluoxetin-induced pulmonary granulomatosis. <i>Eur Respir J</i>. 1996;9(3):615-617. doi:10.1183/09031936.96.09030615<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8730028/pubmed" id="8730028" target="_blank">8730028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536-547. doi:10.1016/j.psym.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31577402">
<a name="31577402"></a>
<i>Depression in children and young people: identification and management</i>. London: National Institute for Health and Care Excellence (UK); June 25, 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31577402/pubmed" id="31577402" target="_blank">31577402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11426073">
<a name="11426073"></a>DeSilva KE, Le Flore DB, Marston BJ, et al, “Serotonin Syndrome in HIV-Infected Individuals Receiving Antiretroviral Therapy and Fluoxetine,” <i>AIDS</i>, 2001, 15(10):1281-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11426073/pubmed" id="11426073" target="_blank">11426073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26660158">
<a name="26660158"></a>Dobson ET, Strawn JR. Pharmacotherapy for pediatric generalized anxiety disorder: a systematic evaluation of efficacy, safety and tolerability. <i>Paediatr Drugs</i>. 2016;18(1):45-53. doi:10.1007/s40272-015-0153-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/26660158/pubmed" id="26660158" target="_blank">26660158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16434782">
<a name="16434782"></a>Dopheide JA, "Recognizing and Treating Depression in Children and Adolescents," <i>Am J Health Syst Pharm</i>, 2006, 63(3):233-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16434782/pubmed" id="16434782" target="_blank">16434782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536379">
<a name="29536379"></a>Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. <i>CNS Drugs</i>. 2018;32(4):321-334. doi:10.1007/s40263-018-0507-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29536379/pubmed" id="29536379" target="_blank">29536379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7649953">
<a name="7649953"></a>Dow SP, Sonies BC, Scheib D, et al, "Practical Guidelines for the Assessment and Treatment of Selective Mutism," <i>J Am Acad Child Adolesc Psychiatry</i>, 1995, 34(7):836-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/7649953/pubmed" id="7649953" target="_blank">7649953</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8875667">
<a name="8875667"></a>Dubovsky SL, Thomas M. Tardive dyskinesia associated with fluoxetine. <i>Psychiatr Serv</i>. 1996;47(9):991-993. doi:10.1176/ps.47.9.991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8875667/pubmed" id="8875667" target="_blank">8875667</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8935208">
<a name="8935208"></a>Dummit ES 3rd, Klein RG, Tancer NK, Asche B, Martin J. Fluoxetine treatment of children with selective mutism: an open trial. <i>J Am Acad Child Adolesc Psychiatry.</i> 1996;35(5):615-621.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8935208/pubmed" id="8935208" target="_blank">8935208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25983210">
<a name="25983210"></a>Durmaz O, Çelik S. Vaginal bleeding associated with antidepressants. <i>Int J Gynaecol Obstet</i>. 2015;130(3):284. doi:10.1016/j.ijgo.2015.03.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25983210/pubmed" id="25983210" target="_blank">25983210</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24631758">
<a name="24631758"></a>Erie JC, Brue SM, Chamberlain AM, Hodge DO. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. <i>Am J Ophthalmol</i>. 2014;158(1):192-197.e1. doi:10.1016/j.ajo.2014.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/24631758/pubmed" id="24631758" target="_blank">24631758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9192539">
<a name="9192539"></a>Fairbanks JM, Pine DS, Tancer NK, et al. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents. <i>J Child Adolesc Psychopharmacol</i>. 1997;7(1):17-29. doi:10.1089/cap.1997.7.17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/9192539/pubmed" id="9192539" target="_blank">9192539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25721705">
<a name="25721705"></a>Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. <i>Psychother Psychosom</i>. 2015;84(2):72-81. doi:10.1159/000370338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25721705/pubmed" id="25721705" target="_blank">25721705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9988054">
<a name="9988054"></a>Fava M, Amsterdam JD, Deltito JA, Salzman C, Schwaller M, Dunner DL. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. <i>Ann Clin Psychiatry</i>. 1998;10(4):145-150.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/9988054/pubmed" id="9988054" target="_blank">9988054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683858">
<a name="16683858"></a>Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(suppl 4):14-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16683858/pubmed" id="16683858" target="_blank">16683858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19621834">
<a name="19621834"></a>Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. <i>Am Fam Physician</i>. 2009;80(3):239-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/19621834/pubmed" id="19621834" target="_blank">19621834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31648376">
<a name="31648376"></a>Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. <i>Acta Psychiatr Scand</i>. 2020;141(1):21-33. doi:10.1111/acps.13120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31648376/pubmed" id="31648376" target="_blank">31648376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fitzcharles.2012">
<a name="Fitzcharles.2012"></a>Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. Canadian guidelines for the diagnosis and management of fibromyalgia syndrome. http://rheum.ca/wp-content/uploads/2017/11/2012CanadianFMGuidelines_17August2012.pdf. Published August 2012. Accessed February 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14728721">
<a name="14728721"></a>Flores G, Perez-Patrigeon S, Cobos-Ayala C, Vergara J. Severe symptomatic hyponatremia during citalopram therapy--a case report. <i>BMC Nephrol</i>. 2004;5:2. doi:10.1186/1471-2369-5-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/14728721/pubmed" id="14728721" target="_blank">14728721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluoxetine.2">
<a name="Fluoxetine.2"></a>Fluoxetine delayed-release capsules [prescribing information]. Bachupally, India: Dr. Reddy's Laboratories Limited; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluoxetine.2020.10">
<a name="Fluoxetine.2020.10"></a>Fluoxetine oral solution [prescribing information]. Philadelphia, PA: Lannett Company Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluoxetine.2020.10">
<a name="Fluoxetine.2020.10"></a>Fluoxetine oral solution [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA, Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluoxetine.4">
<a name="Fluoxetine.4"></a>Fluoxetine tablets [prescribing information]. Bachupally, India: Dr. Reddy's Laboratories Limited; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluoxetine.3">
<a name="Fluoxetine.3"></a>Fluoxetine tablets [prescribing information]. Hauppauge, NY: ScieGen Pharmaceuticals Inc; October 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluoxetine.2020.07">
<a name="Fluoxetine.2020.07"></a>Fluoxetine tablets [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fluoxetine.2023.08">
<a name="Fluoxetine.2023.08"></a>Fluoxetine tablets [prescribing information]. Pine Brook, NJ: Almatica Pharma, Inc; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8599417">
<a name="8599417"></a>Friedenberg FK, Rothstein KD. Hepatitis secondary to fluoxetine treatment. <i>Am J Psychiatry</i>. 1996;153(4):580. doi:10.1176/ajp.153.4.580a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8599417/pubmed" id="8599417" target="_blank">8599417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343-2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gable.2005">
<a name="Gable.2005"></a>Gable KN and Dopheide JA. Psychotropic medication use at a private eating disorders treatment facility: A retrospective chart review and descriptive data analysis. <i>Curr Ther Res Clin Exp.</i> 2005;66:572-588.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27773479">
<a name="27773479"></a>Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-Generation Antidepressants and Hyponatremia Risk: A Population-Based Cohort Study of Older Adults. <i>Am J Kidney Dis</i>. 2017;69(1):87-96. doi:10.1053/j.ajkd.2016.08.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27773479/pubmed" id="27773479" target="_blank">27773479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32215771">
<a name="32215771"></a>Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. <i>Curr Psychiatry Rep</i>. 2020;22(4):20. doi:10.1007/s11920-020-01143-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/32215771/pubmed" id="32215771" target="_blank">32215771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18030077">
<a name="18030077"></a>Gleason MM, Egger HL, Emslie GJ, et al. Psychopharmacological treatment for very young children: Contexts and guidelines. <i>J Am Acad Child Adolesc Psychiatry.</i> 2007;46(12):1532-1572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18030077/pubmed" id="18030077" target="_blank">18030077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9639082">
<a name="9639082"></a>Go FS, Malley EE, Birmaher B, Rosenberg DR. Manic behaviors associated with fluoxetine in three 12- to 18-year-olds with obsessive-compulsive disorder. <i>J Child Adolesc Psychopharmacol</i>. 1998;8(1):73-80. doi:10.1089/cap.1998.8.73<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/9639082/pubmed" id="9639082" target="_blank">9639082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8912507">
<a name="8912507"></a>Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. <i>Arthritis Rheum</i>. 1996;39(11):1852-1859.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8912507/pubmed" id="8912507" target="_blank">8912507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Goldenberg.2019">
<a name="Goldenberg.2019"></a>Goldenberg DL. Treatment of fibromyalgia in adults not responsive to initial therapies. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7781383">
<a name="7781383"></a>Gonzalez-Rothi RJ, Zander DS, Ros PR. Fluoxetine hydrochloride (Prozac)-induced pulmonary disease. <i>Chest</i>. 1995;107(6):1763-1765. doi:10.1378/chest.107.6.1763<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/7781383/pubmed" id="7781383" target="_blank">7781383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243609">
<a name="12243609"></a>Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. <i>Ann Pharmacother</i>. 2002;36(10):1577-1589. doi:10.1345/aph.1A195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12243609/pubmed" id="12243609" target="_blank">12243609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20148751">
<a name="20148751"></a>Grunze H, Vieta E, Goodwin GM, et al; WFSBP Task Force on Treatment Guidelines for Bipolar Disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. <i>World J Biol Psychiatry</i>. 2010;11(2):81-109. doi:10.3109/15622970903555881<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/20148751/pubmed" id="20148751" target="_blank">20148751</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29098925">
<a name="29098925"></a>Grunze H, Vieta E, Goodwin GM, et al; Members of the WFSBP Task Force on Bipolar Affective Disorders working on this topic. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Acute and long-term treatment of mixed states in bipolar disorder. <i>World J Biol Psychiatry</i>. 2018;19(1):2-58. doi:10.1080/15622975.2017.1384850<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29098925/pubmed" id="29098925" target="_blank">29098925</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522259">
<a name="29522259"></a>Grzeskowiak LE, Leggett C, Costi L, Roberts CT, Amir LH. Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study. <i>Br J Clin Pharmacol</i>. 2018;84(6):1373-1379. doi:10.1111/bcp.13575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29522259/pubmed" id="29522259" target="_blank">29522259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506225">
<a name="17506225"></a>Halperin D, Reber G. Influence of antidepressants on hemostasis. <i>Dialogues Clin Neurosci</i>. 2007;9(1):47-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/17506225/pubmed" id="17506225" target="_blank">17506225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332-339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1557494">
<a name="1557494"></a>Hargrave R, Martinez D, Bernstein AJ. Fluoxetine-induced seizures. <i>Psychosomatics</i>. 1992;33(2):236-239. doi:10.1016/s0033-3182(92)72008-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/1557494/pubmed" id="1557494" target="_blank">1557494</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337001">
<a name="29337001"></a>Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? <i>Curr Probl Pediatr Adolesc Health Care</i>. 2018;48(2):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29337001/pubmed" id="29337001" target="_blank">29337001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25351912">
<a name="25351912"></a>Hay P, Chinn D, Forbes D, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of eating disorders. <i>Aust N Z J Psychiatry</i>. 2014;48(11):977-1008. doi:10.1177/0004867414555814<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25351912/pubmed" id="25351912" target="_blank">25351912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12709723">
<a name="12709723"></a>Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. <i>Clin Pharmacol Ther</i>. 2003;73(4):330‐337. doi:10.1016/s0009-9236(02)17634-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12709723/pubmed" id="12709723" target="_blank">12709723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28577352">
<a name="28577352"></a>Heller HM, Ravelli ACJ, Bruning AHL, et al. Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. <i>BMC Pregnancy Childbirth</i>. 2017;17(1):166. doi:10.1186/s12884-017-1334-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28577352/pubmed" id="28577352" target="_blank">28577352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11720696">
<a name="11720696"></a>Hendrick V, Stowe ZN, Altshuler LL, et al. Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk. <i>Biol Psychiatry</i>. 2001;50(10):775-782. doi:10.1016/s0006-3223(01)01197-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11720696/pubmed" id="11720696" target="_blank">11720696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21701626">
<a name="21701626"></a>Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: impact, effects, and treatment. <i>Drug Healthc Patient Saf</i>. 2010;2:141-150. doi:10.2147/DHPS.S7634<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/21701626/pubmed" id="21701626" target="_blank">21701626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019">
<a name="Hirsch.2019"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 28, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2018c">
<a name="Hirsch.2018c"></a>Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 30, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2018b">
<a name="Hirsch.2018b"></a>Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15725429">
<a name="15725429"></a>Holtkamp K, Konrad K, Kaiser N, et al. A retrospective study of SSRI treatment in adolescent anorexia nervosa: insufficient evidence for efficacy. <i>J Psychiatr Res</i>. 2005;39(3):303-310. doi:10.1016/j.jpsychires.2004.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15725429/pubmed" id="15725429" target="_blank">15725429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33386343">
<a name="33386343"></a>Hornberger LL, Lane MA; Committee on Adolescence. Identification and management of eating disorders in children and adolescents. <i>Pediatrics</i>. 2021;147(1):e2020040279. doi:10.1542/peds.2020-040279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/33386343/pubmed" id="33386343" target="_blank">33386343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10812529">
<a name="10812529"></a>Hostetter A, Stowe ZN, Strader JR Jr, McLaughlin E, Llewellyn A. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. <i>Depress Anxiety</i>. 2000;11(2):51‐57.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10812529/pubmed" id="10812529" target="_blank">10812529</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30063169">
<a name="30063169"></a>Ignaszewski MJ, Waslick B. Update on randomized placebo-controlled trials in the past decade for treatment of major depressive disorder in child and adolescent patients: a systematic review. <i>J Child Adolesc Psychopharmacol</i>. 2018;28(10):668-675. doi:10.1089/cap.2017.0174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30063169/pubmed" id="30063169" target="_blank">30063169</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27378473">
<a name="27378473"></a>Ismaili E, Walsh S, O'Brien PMS, et al; Consensus Group of the International Society for Premenstrual Disorders. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. <i>Arch Womens Ment Health</i>. 2016;19(6):953-958. doi:10.1007/s00737-016-0631-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27378473/pubmed" id="27378473" target="_blank">27378473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27249090">
<a name="27249090"></a>Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. <i>J Clin Psychiatry</i>. 2016;77(5):605-611. doi:10.4088/JCP.14r09758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27249090/pubmed" id="27249090" target="_blank">27249090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16896026">
<a name="16896026"></a>Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. <i>Ann Pharmacother</i>. 2006;40(9):1618-1622. doi:10.1345/aph.1G293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16896026/pubmed" id="16896026" target="_blank">16896026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8683851">
<a name="8683851"></a>Javed MA. Priapism associated with fluoxetine therapy: a case report. <i>J Pak Med Assoc</i>. 1996;46(2):45-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8683851/pubmed" id="8683851" target="_blank">8683851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24314591">
<a name="24314591"></a>Jeong BO, Kim SW, Kim SY, Kim JM, Shin IS, Yoon JS. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. <i>Psychosomatics</i>. 2014;55(3):213-220. doi:10.1016/j.psym.2013.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/24314591/pubmed" id="24314591" target="_blank">24314591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1938809">
<a name="1938809"></a>Jerome L. Hypomania with fluoxetine. <i>J Am Acad Child Adolesc Psychiatry</i>. 1991;30(5):850-851.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/1938809/pubmed" id="1938809" target="_blank">1938809</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. <i>Am J Psychiatry</i>. 2018;175(12):1176-1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955469">
<a name="29955469"></a>Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review. <i>Ment Health Clin</i>. 2016;6(4):191-196. doi:10.9740/mhc.2016.07.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29955469/pubmed" id="29955469" target="_blank">29955469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18204349">
<a name="18204349"></a>Jonsson GW, Moosa MY, Jeenah FY. Toxic epidermal necrolysis and fluoxetine: a case report. <i>J Clin Psychopharmacol</i>. 2008;28(1):93-95. doi:10.1097/jcp.0b013e3181604015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18204349/pubmed" id="18204349" target="_blank">18204349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18225967">
<a name="18225967"></a>Kaakeh Y, Stumpf JL. Treatment of selective mutism: focus on selective serotonin reuptake inhibitors. <i>Pharmacotherapy</i>. 2008;28(2):214-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18225967/pubmed" id="18225967" target="_blank">18225967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8863556">
<a name="8863556"></a>Kara H, Aydin S, Yücel M, Agargün MY, Odabaş O, Yilmaz Y. The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. <i>J Urol</i>. 1996;156(5):1631-1632.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8863556/pubmed" id="8863556" target="_blank">8863556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27323598">
<a name="27323598"></a>Kaya T, Yücel M, Eraslan Ö, Cinemre H, Tamer A. Severe hyponatremia, epistaxis, and fluoxetine. <i>J Ayub Med Coll Abbottabad</i>. 2016;28(1):204-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27323598/pubmed" id="27323598" target="_blank">27323598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11297722">
<a name="11297722"></a>Kaye WH, Nagata T, Weltzin TE, et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. <i>Biol Psychiatry</i>. 2001;49(7):644-652. doi:10.1016/s0006-3223(00)01013-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11297722/pubmed" id="11297722" target="_blank">11297722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10645303">
<a name="10645303"></a>Kesavan S, Sobala GM. Serotonin syndrome with fluoxetine plus tramadol. <i>J R Soc Med</i>. 1999;92(9):474-475. doi:10.1177/014107689909200915<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10645303/pubmed" id="10645303" target="_blank">10645303</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790-792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247774">
<a name="30247774"></a>Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis. <i>Int J Geriatr Psychiatry</i>. 2018;33(12):1688-1708. doi:10.1002/gps.4974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30247774/pubmed" id="30247774" target="_blank">30247774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Khera.2018">
<a name="Khera.2018"></a>Khera M, Cunningham GR. Treatment of male sexual dysfunction. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 24, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16433870">
<a name="16433870"></a>Kim J, Riggs KW, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. <i>Br J Clin Pharmacol</i>. 2006;61(2):155‐163. doi:10.1111/j.1365-2125.2005.02538.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16433870/pubmed" id="16433870" target="_blank">16433870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31206390">
<a name="31206390"></a>Kim S, Ko YJ, Park K, Yang BR, Kim MS, Park BJ. Fluoxetine and risk of bleeding in patients aged 60 years and older using the Korea Adverse Event Reporting System Database: a case/noncase study. <i>J Clin Psychopharmacol</i>. 2019;39(4):362-366. doi:10.1097/JCP.0000000000001059<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31206390/pubmed" id="31206390" target="_blank">31206390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7875951">
<a name="7875951"></a>King RA, Segman RH, Anderson GM. Serotonin and suicidality: the impact of acute fluoxetine administration. I: Serotonin and suicide. <i>Isr J Psychiatry Relat Sci</i>. 1994;31(4):271-279.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/7875951/pubmed" id="7875951" target="_blank">7875951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993931">
<a name="27993931"></a>Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. <i>Evid Based Ment Health</i>. 2017;20(1):27. doi:10.1136/eb-2016-102528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27993931/pubmed" id="27993931" target="_blank">27993931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2786344">
<a name="2786344"></a>Kline MD. Fluoxetine and anorgasmia. <i>Am J Psychiatry</i>. 1989;146(6):804-805. doi:10.1176/ajp.146.6.804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/2786344/pubmed" id="2786344" target="_blank">2786344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17849776">
<a name="17849776"></a>Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB; American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. <i>Am J Psychiatry</i>. 2007;164(7)(suppl):S5-S53.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/17849776/pubmed" id="17849776" target="_blank">17849776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14642021">
<a name="14642021"></a>Kotler LA, Devlin MJ, Davies M, et al. An open trial of fluoxetine for adolescents with bulimia nervosa. <i>J Child Adolesc Psychopharmacol.</i> 2003;13(3):329-335.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/14642021/pubmed" id="14642021" target="_blank">14642021</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31447707">
<a name="31447707"></a>Kotapati VP, Khan AM, Dar S, et al. The effectiveness of selective serotonin reuptake inhibitors for treatment of obsessive-compulsive disorder in adolescents and children: a systematic review and meta-analysis. <i>Front Psychiatry</i>. 2019;10:523. doi:10.3389/fpsyt.2019.00523<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31447707/pubmed" id="31447707" target="_blank">31447707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10583022">
<a name="10583022"></a>Kristensen JH, Ilett KF, Hackett LP, Yapp P, Paech M, Begg EJ. Distribution and excretion of fluoxetine and norfluoxetine in human milk. <i>Br J Clin Pharmacol</i>. 1999;48(4):521-527. doi:10.1046/j.1365-2125.1999.00040.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10583022/pubmed" id="10583022" target="_blank">10583022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kupka.2018">
<a name="Kupka.2018"></a>Kupka R. Rapid cycling bipolar disorder in adults: Treatment of major depression. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21948719">
<a name="21948719"></a>Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. <i>CMAJ</i>. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/21948719/pubmed" id="21948719" target="_blank">21948719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10755580">
<a name="10755580"></a>Lake MB, Birmaher B, Wassick S, Mathos K, Yelovich AK. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. <i>J Child Adolesc Psychopharmacol</i>. 2000;10(1):35-38. doi:10.1089/cap.2000.10.35<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10755580/pubmed" id="10755580" target="_blank">10755580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31078196">
<a name="31078196"></a>Lanza di Scalea T, Pearlstein T. Premenstrual dysphoric disorder. <i>Med Clin North Am</i>. 2019;103(4):613-628. doi:10.1016/j.mcna.2019.02.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31078196/pubmed" id="31078196" target="_blank">31078196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3871765">
<a name="3871765"></a>Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. <i>J Clin Psychiatry</i>. 1985;46(3, pt 2):14-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/3871765/pubmed" id="3871765" target="_blank">3871765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16912031">
<a name="16912031"></a>Leombruni P, Amianto F, Delsedime N, Gramaglia C, Abbate-Daga G, Fassino S. Citalopram versus fluoxetine for the treatment of patients with bulimia nervosa: a single-blind randomized controlled trial. <i>Adv Ther</i>. 2006;23(3):481-494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16912031/pubmed" id="16912031" target="_blank">16912031</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18598735">
<a name="18598735"></a>Leombruni P, Pierò A, Lavagnino L, Brustolin A, Campisi S, Fassino S. A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with binge eating disorder. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2008;32(6):1599-1605. doi:10.1016/j.pnpbp.2008.06.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18598735/pubmed" id="18598735" target="_blank">18598735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786-1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8282672">
<a name="8282672"></a>Lester BM, Cucca J, Andreozzi L, Flanagan P, Oh W. Possible association between fluoxetine hydrochloride and colic in an infant. <i>J Am Acad Child Adolesc Psychiatry</i>. 1993;32(6):1253-1255. doi:10.1097/00004583-199311000-00020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8282672/pubmed" id="8282672" target="_blank">8282672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8195457">
<a name="8195457"></a>Levine R, Kenin M, Hoffman JS, Day-Knepple E. Grand mal seizures associated with the use of fluoxetine. <i>J Clin Psychopharmacol</i>. 1994;14(2):145-146. doi:10.1097/00004714-199404000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8195457/pubmed" id="8195457" target="_blank">8195457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16461873">
<a name="16461873"></a>Levinson-Castiel R, Merlob P, Linder N, et al, "Neonatal Abstinence Syndrome After <i>in utero</i> Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants," <i>Arch Pediatr Adolesc Med</i>, 2006, 160(2):173-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16461873/pubmed" id="16461873" target="_blank">16461873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8666216">
<a name="8666216"></a>Levy NB, Blumenfield M, Beasley CM Jr, et al. Fluoxetine in depressed patients with renal failure and in depressed patients with normal kidney function. <i>Gen Hosp Psychiatry</i>. 1996;18(1):8-13. doi:10.1016/0163-8343(95)00073-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8666216/pubmed" id="8666216" target="_blank">8666216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18188866">
<a name="18188866"></a>Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. <i>Pharmacoepidemiol Drug Saf</i>. 2008;17(4):328-335. doi:10.1002/pds.1546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18188866/pubmed" id="18188866" target="_blank">18188866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12447029">
<a name="12447029"></a>Liebowitz MR, Turner SM, Piacentini J, et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. <i>J Am Acad Child Adolesc Psychiatry</i>. 2002;41(12):1431-1438. doi:10.1097/00004583-200212000-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12447029/pubmed" id="12447029" target="_blank">12447029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8804257">
<a name="8804257"></a>Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports [published correction appears in Can Med Assoc J 1996 Oct 15;155(8):1043]. <i>CMAJ</i>. 1996;155(5):519-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8804257/pubmed" id="8804257" target="_blank">8804257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35760074">
<a name="35760074"></a>Liu Q, Gao H, Huang Y, Wang M, Jiang H, Dai Y, Zhang X. Comparison of fluoxetine with other selective serotonin reuptake inhibitors in the treatment of premature ejaculation: a systematic review and meta-analysis. <i>Andrologia</i>. 2022;54(8):e14500. doi:10.1111/and.14500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/35760074/pubmed" id="35760074" target="_blank">35760074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25901778">
<a name="25901778"></a>Lock J, La Via MC; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter for the assessment and treatment of children and adolescents with eating disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2015;54(5):412-425. doi:10.1016/j.jaac.2015.01.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25901778/pubmed" id="25901778" target="_blank">25901778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17919277">
<a name="17919277"></a>Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. <i>Aliment Pharmacol Ther</i>. 2008;27(1):31-40. doi:10.1111/j.1365-2036.2007.03541.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/17919277/pubmed" id="17919277" target="_blank">17919277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27377815">
<a name="27377815"></a>Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. <i>Ann Rheum Dis</i>. 2017;76(2):318-328. doi:10.1136/annrheumdis-2016-209724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27377815/pubmed" id="27377815" target="_blank">27377815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 6. Special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588‐603. doi:10.1177/0706743716659276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7993290">
<a name="7993290"></a>Mander A, McCausland M, Workman B, Flamer H, Christophidis N. Fluoxetine induced dyskinesia. <i>Aust N Z J Psychiatry</i>. 1994;28(2):328-330. doi:10.1080/00048679409075647<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/7993290/pubmed" id="7993290" target="_blank">7993290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24094459">
<a name="24094459"></a>Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. <i>Maturitas</i>. 2013;76(4):357-363. doi:10.1016/j.maturitas.2013.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/24094459/pubmed" id="24094459" target="_blank">24094459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19965920">
<a name="19965920"></a>Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al. Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. <i>J Clin Endocrinol Metab</i>. 2010;95(2):837-846. doi:10.1210/jc.2009-1575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/19965920/pubmed" id="19965920" target="_blank">19965920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12356658">
<a name="12356658"></a>Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A. Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder. <i>Br J Psychiatry</i>. 2002b;181:315-320. doi:10.1192/bjp.181.4.315<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12356658/pubmed" id="12356658" target="_blank">12356658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11926718">
<a name="11926718"></a>Martenyi F, Brown EB, Zhang H, Prakash A, Koke SC. Fluoxetine versus placebo in posttraumatic stress disorder. <i>J Clin Psychiatry</i>. 2002a;63(3):199-206. doi:10.4088/jcp.v63n0305<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11926718/pubmed" id="11926718" target="_blank">11926718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289250">
<a name="15289250"></a>Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. <i>Arch Pediatr Adolesc Med</i>. 2004;158(8):773-780. doi:10.1001/archpedi.158.8.773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15289250/pubmed" id="15289250" target="_blank">15289250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30170040">
<a name="30170040"></a>Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. <i>Am J Obstet Gynecol</i>. 2019;220(1):57.e1-57.e13. doi:10.1016/j.ajog.2018.08.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30170040/pubmed" id="30170040" target="_blank">30170040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201-209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25248846">
<a name="25248846"></a>Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. <i>Clin Pharmacokinet</i>. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25248846/pubmed" id="25248846" target="_blank">25248846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21464191">
<a name="21464191"></a>McPheeters ML, Warren Z, Sathe N, et al, "A Systematic Review of Medical Treatments for Children With Autism Spectrum Disorders," <i>Pediatrics</i>, 2011, 127(5):e1312-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/21464191/pubmed" id="21464191" target="_blank">21464191</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-McVoy.1">
<a name="McVoy.1"></a>McVoy M, Findling RL, eds. <i>Clinical Manual of Child and Adolescent Psychopharmacology</i>. 3rd ed. Amer Psychiatric Pub; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10755087">
<a name="10755087"></a>Michael A, Mayer C. Fluoxetine-induced anaesthesia of vagina and nipples. <i>Br J Psychiatry</i>. 2000;176:299. doi:10.1192/bjp.176.3.299-a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10755087/pubmed" id="10755087" target="_blank">10755087</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2589557">
<a name="2589557"></a>Miller LG, Bowman RC, Mann D, Tripathy A. A case of fluoxetine-induced serum sickness. <i>Am J Psychiatry</i>. 1989;146(12):1616-1617. doi:10.1176/ajp.146.12.1616<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/2589557/pubmed" id="2589557" target="_blank">2589557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11229449">
<a name="11229449"></a>Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. <i>J Clin Psychiatry</i>. 2001;62 Suppl 3:10-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11229449/pubmed" id="11229449" target="_blank">11229449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9292833">
<a name="9292833"></a>Montejo-González AL, Llorca G, Izquierdo JA, et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. <i>J Sex Marital Ther</i>. 1997;23(3):176-194. doi:10.1080/00926239708403923<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/9292833/pubmed" id="9292833" target="_blank">9292833</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14581256">
<a name="14581256"></a>Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. <i>Arch Intern MedMurray MJ, Hooberman D. Fluoxetine and prolonged erection. Am J Psychiatry. 1993;150(1):167-168. doi:10.1176/ajp.150.1.167b</i>. 2003;163(19):2354-2358. doi:10.1001/archinte.163.19.2354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/14581256/pubmed" id="14581256" target="_blank">14581256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30397569">
<a name="30397569"></a>Mullen S. Major depressive disorder in children and adolescents. <i>Ment Health Clin</i>. 2018;8(6):275-283. doi:10.9740/mhc.2018.11.275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30397569/pubmed" id="30397569" target="_blank">30397569</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25175904">
<a name="25175904"></a>Mullish BH, Kabir MS, Thursz MR, Dhar A. Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation. <i>Aliment Pharmacol Ther</i>. 2014;40(8):880-892. doi:10.1111/apt.12925<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25175904/pubmed" id="25175904" target="_blank">25175904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8417566">
<a name="8417566"></a>Murray MJ, Hooberman D. Fluoxetine and prolonged erection. <i>Am J Psychiatry</i>. 1993;150(1):167-168. doi:10.1176/ajp.150.1.167b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8417566/pubmed" id="8417566" target="_blank">8417566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132433">
<a name="22132433"></a>National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/22132433/pubmed" id="22132433" target="_blank">22132433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31577402">
<a name="31577402"></a>National Institute for Health and Care Excellence (NICE). Depression in children and young people: identification and management. London: National Institute for Health and Care Excellence (NICE); 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31577402/pubmed" id="31577402" target="_blank">31577402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21453380">
<a name="21453380"></a>Nelson JC and Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. <i>J Am Geriatr Soc.</i> 2011;59(4):577-585.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/21453380/pubmed" id="21453380" target="_blank">21453380</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23624686">
<a name="23624686"></a>Nevatte T, O'Brien PM, Bäckström T, et al; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. <i>Arch Womens Ment Health</i>. 2013;16(4):279-291. doi:10.1007/s00737-013-0346-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/23624686/pubmed" id="23624686" target="_blank">23624686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30407100">
<a name="30407100"></a>Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an update meta-analysis. <i>J Womens Health (Larchmt)</i>. 2019;28(3):331-338. doi:10.1089/jwh.2018.7319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30407100/pubmed" id="30407100" target="_blank">30407100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract</i>. 2013;26(4):389-396. doi:10.1177/0897190012467210<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460039">
<a name="18460039"></a>Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. <i>Br J Clin Pharmacol</i>. 2008;66(1):76-81. doi:10.1111/j.1365-2125.2008.03154.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18460039/pubmed" id="18460039" target="_blank">18460039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25572308">
<a name="25572308"></a>Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. <i>Hum Psychopharmacol</i>. 2015;30(1):4-20. doi:10.1002/hup.2451<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25572308/pubmed" id="25572308" target="_blank">25572308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18317501">
<a name="18317501"></a>Ozturk S, Ozsenel EB, Kazancioglu R, Turkmen A. A case of fluoxetine-induced syndrome of inappropriate antidiuretic hormone secretion. <i>Nat Clin Pract Nephrol</i>. 2008;4(5):278-282. doi:10.1038/ncpneph0780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18317501/pubmed" id="18317501" target="_blank">18317501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8826562">
<a name="8826562"></a>Pai VB, Kelly MW. Bruising associated with the use of fluoxetine. <i>Ann Pharmacother</i>. 1996;30(7-8):786-788. doi:10.1177/106002809603000716<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8826562/pubmed" id="8826562" target="_blank">8826562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27999518">
<a name="27999518"></a>Patel DD, Galarneau D. Serotonin syndrome with fluoxetine: two case reports. <i>Ochsner J</i>. 2016;16(4):554-557.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27999518/pubmed" id="27999518" target="_blank">27999518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26667012">
<a name="26667012"></a>Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. <i>BMJ Open</i>. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/26667012/pubmed" id="26667012" target="_blank">26667012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15507582">
<a name="15507582"></a>Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. <i>JAMA</i>. 2004;292(16):1969-1976. doi:10.1001/jama.292.16.1969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15507582/pubmed" id="15507582" target="_blank">15507582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11926939">
<a name="11926939"></a>Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. <i>Arch Gen Psychiatry</i>. 2002;59(4):381-388.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11926939/pubmed" id="11926939" target="_blank">11926939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phillips.2018">
<a name="Phillips.2018"></a>Phillips KA. Body dysmorphic disorder: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 24, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18325859">
<a name="18325859"></a>Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. <i>Body Image</i>. 2008;5(1):13-27. doi:10.1016/j.bodyim.2007.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18325859/pubmed" id="18325859" target="_blank">18325859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29557689">
<a name="29557689"></a>Pogliani L, Baldelli S, Cattaneo D, et al. Selective serotonin reuptake inhibitors' passage into human milk of lactating women. <i>J Matern Fetal Neonatal Med</i>. 2019;32(18):3020-3025. doi:10.1080/14767058.2018.1455180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29557689/pubmed" id="29557689" target="_blank">29557689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22176943">
<a name="22176943"></a>Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2012;51(1):98-113. doi:10.1016/j.jaac.2011.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/22176943/pubmed" id="22176943" target="_blank">22176943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29588433">
<a name="29588433"></a>Preeti S, Jayaram SD, Chittaranjan A. Sexual dysfunction in patients with antidepressant-treated anxiety or depressive disorders: a pragmatic multivariable longitudinal study. <i>East Asian Arch Psychiatry</i>. 2018;28(1):9-16.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29588433/pubmed" id="29588433" target="_blank">29588433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prozac.2020.04">
<a name="Prozac.2020.04"></a>Prozac (fluoxetine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prozac.2020.04">
<a name="Prozac.2020.04"></a>Prozac (fluoxetine) [prescribing information]. Indianapolis, IN: Lilly USA LLC; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prozac.2016.07">
<a name="Prozac.2016.07"></a>Prozac (fluoxetine) [product monograph]. Toronto, Ontario, Canada: Eli Lilly Canada Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, Bruyère O, Reginster JY. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137. doi:10.1007/s00198-012-2015-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26156519">
<a name="26156519"></a>Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; National Birth Defects Prevention Study. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. <i>BMJ</i>. 2015;351:h3190. doi:10.1136/bmj.h3190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/26156519/pubmed" id="26156519" target="_blank">26156519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci Ther</i>. 2010;16(4):227-234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23596418">
<a name="23596418"></a>Renoir T. Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved. <i>Front Pharmacol</i>. 2013;4:45. doi:10.3389/fphar.2013.00045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/23596418/pubmed" id="23596418" target="_blank">23596418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242321">
<a name="17242321"></a>Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. <i>Arch Intern Med</i>. 2007;167(2):188-194. doi:10.1001/archinte.167.2.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/17242321/pubmed" id="17242321" target="_blank">17242321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613. doi:10.1016/j.bone.2012.05.018<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11199947">
<a name="11199947"></a>Romano S, Goodman W, Tamura R, Gonzales J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. <i>J Clin Psychopharmacol</i>. 2001;21(1):46-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/11199947/pubmed" id="11199947" target="_blank">11199947</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21115584">
<a name="21115584"></a>Rosen DS, American Academy of Pediatrics Committee on Adolescence. Identification and management of eating disorders in children and adolescents. <i>Pediatrics.</i> 2010;126(6):1240-1253.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/21115584/pubmed" id="21115584" target="_blank">21115584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19630612">
<a name="19630612"></a>Rosenberg DR, Johnson K, Sahl R. Evolving mania in an adolescent treated with low-dose fluoxetine. <i>J Child Adolesc Psychopharmacol</i>. 1992;2(4):299-306. doi:10.1089/cap.1992.2.299<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/19630612/pubmed" id="19630612" target="_blank">19630612</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15232326">
<a name="15232326"></a>Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. <i>J Clin Psychopharmacol</i>. 2004;24(4):365-373.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15232326/pubmed" id="15232326" target="_blank">15232326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16553536">
<a name="16553536"></a>Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. <i>J Child Adolesc Psychopharmacol</i>. 2006;16(1-2):159-169. doi:10.1089/cap.2006.16.159<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16553536/pubmed" id="16553536" target="_blank">16553536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27834194">
<a name="27834194"></a>Samuel NG, Seifert CF. Risk of bleeding in patients on full-dose enoxaparin with venous thromboembolism and selective serotonin reuptake inhibitors. <i>Ann Pharmacother</i>. 2017;51(3):226-231. doi:10.1177/1060028016677309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27834194/pubmed" id="27834194" target="_blank">27834194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sarafem.2017.01">
<a name="Sarafem.2017.01"></a>Sarafem (fluoxetine) [prescribing information]. Madison, NJ: Allergan USA Inc; September 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sarafem.2006.08">
<a name="Sarafem.2006.08"></a>Sarafem Pulvules (fluoxetine) [prescribing information]. Rockaway, NJ: Eli Lilly and Company; August 9, 2006.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683860">
<a name="16683860"></a>Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16683860/pubmed" id="16683860" target="_blank">16683860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3262026">
<a name="3262026"></a>Schenker S, Bergstrom RF, Wolen RL, Lemberger L. Fluoxetine disposition and elimination in cirrhosis. <i>Clin Pharmacol Ther</i>. 1988;44(3):353-359. doi:10.1038/clpt.1988.161<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/3262026/pubmed" id="3262026" target="_blank">3262026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32238008">
<a name="32238008"></a>Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opin Drug Metab Toxicol</i>. 2020;16(5):431‐440. doi:10.1080/17425255.2020.1750598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/32238008/pubmed" id="32238008" target="_blank">32238008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19440080">
<a name="19440080"></a>Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. <i>J Clin Psychopharmacol</i>. 2009;29(3):259-266. doi:10.1097/JCP.0b013e3181a5233f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/19440080/pubmed" id="19440080" target="_blank">19440080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6362443">
<a name="6362443"></a>Settle EC Jr, Settle GP. A case of mania associated with fluoxetine. <i>Am J Psychiatry</i>. 1984;141(2):280-281. doi:10.1176/ajp.141.2.280<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/6362443/pubmed" id="6362443" target="_blank">6362443</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25540831">
<a name="25540831"></a>Shakoor M, Ayub S, Ahad A, Ayub Z. Transient serotonin syndrome caused by concurrent use of tramadol and selective serotonin reuptake inhibitor. <i>Am J Case Rep</i>. 2014;15:562-564. doi:10.12659/AJCR.892264<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25540831/pubmed" id="25540831" target="_blank">25540831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34961344">
<a name="34961344"></a>Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA/SMSNA guideline. <i>J Urol</i>. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/34961344/pubmed" id="34961344" target="_blank">34961344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simpson.2018">
<a name="Simpson.2018"></a>Simpson HB. Pharmacotherapy for obsessive-compulsive disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 3, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31808410">
<a name="31808410"></a>Siroosbakht S, Rezakhaniha S, Rezakhaniha B. Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial. <i>Int Braz J Urol</i>. 2019;45(6):1209‐1215. doi:10.1590/S1677-5538.IBJU.2019.0121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31808410/pubmed" id="31808410" target="_blank">31808410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20631556">
<a name="20631556"></a>Sit D, Perel JM, Luther JF, Wisniewski SR, Helsel JC, Wisner KL. Disposition of chiral and racemic fluoxetine and norfluoxetine across childbearing. <i>J Clin Psychopharmacol</i>. 2010;30(4):381‐386. doi:10.1097/JCP.0b013e3181e7be23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/20631556/pubmed" id="20631556" target="_blank">20631556</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31035856">
<a name="31035856"></a>Slomian J, Honvo G, Emonts P, Reginster JY, Bruyère O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. <i>Womens Health (Lond)</i>. 2019;15:1745506519844044. doi:10.1177/1745506519844044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31035856/pubmed" id="31035856" target="_blank">31035856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31140587">
<a name="31140587"></a>Sobieraj DM, Martinez BK, Hernandez AV, et al. Adverse effects of pharmacologic treatments of major depression in older adults. <i>J Am Geriatr Soc</i>. 2019;67(8):1571-1581. doi:10.1111/jgs.15966<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/31140587/pubmed" id="31140587" target="_blank">31140587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10333979">
<a name="10333979"></a>Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. <i>J Affect Disord</i>. 1998;51(3):215-235. doi:10.1016/s0165-0327(98)00221-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/10333979/pubmed" id="10333979" target="_blank">10333979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.2018">
<a name="Stein.2018"></a>Stein MB. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 15, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25449861">
<a name="25449861"></a>Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA. Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. <i>Depress Anxiety</i>. 2015;32(3):149-157. doi:10.1002/da.22329<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25449861/pubmed" id="25449861" target="_blank">25449861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467827">
<a name="27467827"></a>Süleyman A, Kurt FS, Soyata AZ, Kaya I, Alyanak B. Henoch-Schönlein purpura during treatment with fluoxetine. <i>J Child Adolesc Psychopharmacol</i>. 2016;26(7):651. doi:10.1089/cap.2016.0045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27467827/pubmed" id="27467827" target="_blank">27467827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587-596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30676405">
<a name="30676405"></a>Sylvester C, Menke M, Gopalan P. Selective serotonin reuptake inhibitors and fertility: considerations for couples trying to conceive. <i>Harv Rev Psychiatry</i>. 2019;27(2):108-118. doi:10.1097/HRP.0000000000000204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30676405/pubmed" id="30676405" target="_blank">30676405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sysko.2018">
<a name="Sysko.2018"></a>Sysko R, Devlin M. Binge eating disorder in adults: Overview of treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 3, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8932542">
<a name="8932542"></a>Taddio A, Ito S, and Koren G, "Excretion of Fluoxetine and its Metabolite, Norfluoxetine, in Human Breast Milk," <i>J Clin Pharmacol</i>, 1996, 36(1):42-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/8932542/pubmed" id="8932542" target="_blank">8932542</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20633754">
<a name="20633754"></a>Tan Pei Lin L, Kwek SK. Onset of psoriasis during therapy with fluoxetine. <i>Gen Hosp Psychiatry</i>. 2010;32(4):446.e9-446.e10. doi:10.1016/j.genhosppsych.2009.08.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/20633754/pubmed" id="20633754" target="_blank">20633754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19491861">
<a name="19491861"></a>Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2009;104(6):1475-1482. doi:10.1038/ajg.2009.128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/19491861/pubmed" id="19491861" target="_blank">19491861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17088502">
<a name="17088502"></a>Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. <i>Arch Gen Psychiatry</i>. 2006;63(11):1217-23. doi:10.1001/archpsyc.63.11.1217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/17088502/pubmed" id="17088502" target="_blank">17088502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2301661">
<a name="2301661"></a>Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. <i>Am J Psychiatry</i>. 1990;147(2):207-210. doi:10.1176/ajp.147.2.207<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/2301661/pubmed" id="2301661" target="_blank">2301661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14609883">
<a name="14609883"></a>Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression [published correction appears in <i>Arch Gen Psychiatry</i>. 2004;61(2):176]. <i>Arch Gen Psychiatry</i>. 2003;60(11):1079-1088.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/14609883/pubmed" id="14609883" target="_blank">14609883</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28766108">
<a name="28766108"></a>Tomlin AM, Reith DM, Woods DJ, et al. A pharmacoepidemiology database system for monitoring risk due to the use of medicines by New Zealand primary care patients. <i>Drug Saf</i>. 2017;40(12):1259-1277. doi:10.1007/s40264-017-0579-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28766108/pubmed" id="28766108" target="_blank">28766108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958306">
<a name="19958306"></a>Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. <i>Acta Psychiatr Scand</i>. 2010;121(6):404-414. doi:10.1111/j.1600-0447.2009.01514.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/19958306/pubmed" id="19958306" target="_blank">19958306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29073757">
<a name="29073757"></a>Tuman TC, Tuman B, Polat M, Çakır U. Urticaria and Angioedema Associated with Fluoxetine. <i>Clin Psychopharmacol Neurosci</i>. 2017;15(4):418-419. doi:10.9758/cpn.2017.15.4.418<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29073757/pubmed" id="29073757" target="_blank">29073757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25749013">
<a name="25749013"></a>Türkoğlu S, Türkoğlu G. Vaginal bleeding and hemorrhagic prepatellar bursitis in a preadolescent girl, possibly related to fluoxetine. <i>J Child Adolesc Psychopharmacol</i>. 2015;25(2):186-187. doi:10.1089/cap.2014.0124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25749013/pubmed" id="25749013" target="_blank">25749013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15617511">
<a name="15617511"></a>Ursano RJ, Bell C, Eth S, et al; Work Group on ASD and PTSD; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. <i>Am J Psychiatry</i>. 2004;161(11)(suppl):S3-S31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15617511/pubmed" id="15617511" target="_blank">15617511</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USVADoD.2017">
<a name="USVADoD.2017"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. Version 3.0. <a href="https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf</a>. Published 2017. Accessed July 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15906018">
<a name="15906018"></a>van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. <i>Eur J Clin Pharmacol</i>. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15906018/pubmed" id="15906018" target="_blank">15906018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27663940">
<a name="27663940"></a>Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2016;55(10):851-859.e2. doi:10.1016/j.jaac.2016.07.768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27663940/pubmed" id="27663940" target="_blank">27663940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18219438">
<a name="18219438"></a>Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. <i>Calcif Tissue Int</i>. 2008;82(2):92-101. doi:10.1007/s00223-007-9099-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/18219438/pubmed" id="18219438" target="_blank">18219438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28523892">
<a name="28523892"></a>Vignesh P, Kishore J, Kumar A, et al. A young child with eosinophilia, rash, and multisystem illness: drug rash, eosinophilia, and systemic symptoms syndrome after receipt of fluoxetine. <i>Pediatr Dermatol</i>. 2017;34(3):e120-e125. doi:10.1111/pde.13131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28523892/pubmed" id="28523892" target="_blank">28523892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775508">
<a name="30775508"></a>Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: A review of clinical studies and plausible mechanisms. <i>Osteoporos Sarcopenia</i>. 2017;3(2):75-81. doi:10.1016/j.afos.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/30775508/pubmed" id="30775508" target="_blank">30775508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26003261">
<a name="26003261"></a>Waldinger MD. Psychiatric disorders and sexual dysfunction. <i>Handb Clin Neurol</i>. 2015;130:469-489. doi:10.1016/B978-0-444-63247-0.00027-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/26003261/pubmed" id="26003261" target="_blank">26003261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16772623">
<a name="16772623"></a>Walsh BT, Kaplan AS, Attia E, et al. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. <i>JAMA</i>. 2006;295(22):2605-2612. doi:10.1001/jama.295.22.2605<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16772623/pubmed" id="16772623" target="_blank">16772623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32439401">
<a name="32439401"></a>Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/32439401/pubmed" id="32439401" target="_blank">32439401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26126579">
<a name="26126579"></a>Wang CY, Fu SH, Wang CL, Chen PJ, Wu FL, Hsiao FY. Serotonergic antidepressant use and the risk of fracture: a population-based nested case-control study. <i>Osteoporos Int</i>. 2016;27(1):57-63. doi:10.1007/s00198-015-3213-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/26126579/pubmed" id="26126579" target="_blank">26126579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wang.1">
<a name="Wang.1"></a>Wang Z, Whiteside S, Sim L, et al. Anxiety in Children. Comparative Effectiveness Review No. 192. (Prepared by the Mayo Clinic Evidence-based Practice Center under Contract No. 290-2015-00013-I.) AHRQ Publication No. 17-EHC023-EF. Rockville, MD: Agency for Healthcare Research and Quality; August 2017. Erratum July 2018. doi:10.23970/AHRQEPCCER192</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27495351">
<a name="27495351"></a>Warden SJ, Fuchs RK. Do selective serotonin reuptake inhibitors (SSRIs) cause fractures? <i>Curr Osteoporos Rep</i>. 2016;14(5):211-218. doi:10.1007/s11914-016-0322-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/27495351/pubmed" id="27495351" target="_blank">27495351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28141599">
<a name="28141599"></a>Wee TC. Gastrointestinal hemorrhage related to fluoxetine in a patient with stroke. <i>Am J Phys Med Rehabil</i>. 2017;96(11):e201-e203. doi:10.1097/PHM.0000000000000708<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28141599/pubmed" id="28141599" target="_blank">28141599</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12090838">
<a name="12090838"></a>Weintrob N, Cohen D, Klipper-Aurbach Y, et al, “Decreased Growth During Therapy With Selective Serotonin Reuptake Inhibitors,” <i>Arch Pediatr Adolesc Med</i>, 2002, 156(7):696-701.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/12090838/pubmed" id="12090838" target="_blank">12090838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15169695">
<a name="15169695"></a>Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. <i>Am J Psychiatry</i>. 2004;161(6):1066-1078. doi:10.1176/appi.ajp.161.6.1066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/15169695/pubmed" id="15169695" target="_blank">15169695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22114630">
<a name="22114630"></a>Wenzel-Seifert K, Wittmann M, Haen E. QTc prolongation by psychotropic drugs and the risk of torsade de pointes. <i>Dtsch Arztebl Int</i>. 2011;108(41):687-693. doi:10.3238/arztebl.2011.0687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/22114630/pubmed" id="22114630" target="_blank">22114630</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28708853">
<a name="28708853"></a>Westin AA, Brekke M, Molden E, Skogvoll E, Spigset O. Selective serotonin reuptake inhibitors and venlafaxine in pregnancy: Changes in drug disposition. <i>PLoS One</i>. 2017;12(7):e0181082. doi:10.1371/journal.pone.0181082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28708853/pubmed" id="28708853" target="_blank">28708853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873955">
<a name="29873955"></a>Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. <i>J Clin Psychiatry</i>. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/29873955/pubmed" id="29873955" target="_blank">29873955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953843">
<a name="28953843"></a>Womersley K, Ripullone K, Agius M. What are the risks associated with different selective serotonin re-uptake inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. <i>Psychiatr Danub</i>. 2017;29(suppl 3):629-644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28953843/pubmed" id="28953843" target="_blank">28953843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28118168">
<a name="28118168"></a>Yektaş Ç, Tufan AE. Increased trichotillomania symptoms in a child with fluoxetine treatment. <i>Clin Neuropharmacol</i>. 2017;40(2):95-96. doi:10.1097/WNF.0000000000000205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/28118168/pubmed" id="28118168" target="_blank">28118168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25822478">
<a name="25822478"></a>Yucel A, Yucel N, Ozcan H, Gulec M, Aydin A. Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases. <i>J Clin Psychopharmacol</i>. 2015;35(3):354-355. doi:10.1097/JCP.0000000000000301<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fluoxetine-drug-information/abstract-text/25822478/pubmed" id="25822478" target="_blank">25822478</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8465 Version 759.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
